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ABSTRACT 
KIRSTON BARTON: Targeting the Class I HDACs to Disrupt Quiescent HIV 
Proviruses 
(Under the direction of David Margolis) 
 
 Infection with the human immunodeficiency virus type 1 (HIV-1) was first 
described in a report in the Morbidity and Mortality Weekly Report in June of 1981. 
Since that time millions of people around that world have been affected by HIV-1 
infection. In the last three decades, significant advances have been made in the 
treatment of people who are infected with HIV-1. However, there is still no cure for 
HIV-1 infection. The primary obstacle to viral clearance is the existence of long-lived 
cells harboring replication competent quiescent proviruses. One approach that has 
been proposed for elimination of this replication competent virus from infected 
patients is called the "induce and clear" method. This dissertation focuses on 
identifying factors that could potentially be used as therapeutic targets for induction 
of quiescent HIV-1 proviruses. 
 c-Myc and YY1 are two well-known transcription factors that have been 
demonstrated to bind to the HIV-1 long terminal repeat (LTR) and recruit repressive 
histone deacetylase (HDAC) enzymes. Therefore, the hypothesis was that 
specifically targeting factors that recruit HDAC to the HIV-1 promoter would be 
sufficient to disrupt occupancy of the HDACs and induce expression from quiescent 
proviruses. The results demonstrate that depletion of YY1 is sufficient to induce 
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expression from quiescent proviruses in two models of HIV-1 latency; however, it did 
not affect the residence of HDACs at the HIV-1 LTR.  
To further identify specific targets for disruption of quiescent HIV-1, the next 
step was to elucidate which of the class I HDACs was important for the strong 
induction of transcription from HIV-1 promoters following treatment with class I 
selective HDAC inhibitors. Individual depletion of HDAC1, -2, and -3 demonstrated 
that depletion of HDAC1 and HDAC2 does not affect transcription from the HIV-1 
promoter; however, depletion of HDAC3 does significantly induce transcription from 
quiescent HIV-1 promoters, indicating that it may be possible to reverse latency 
using therapeutics targeting HDAC3.  
The overall conclusions of this thesis indicate that redundant mechanisms of 
HDAC recruitment are present at HIV-1 LTRs and therefore depletion of HDAC 
recruiters may not be sufficient to disrupt latency. However, HDAC3 is a potential 
therapeutic target for induction of transcription from the HIV-1 promoter.  
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CHAPTER 1 
BACKGROUND AND SIGNIFICANCE1  
 
Introduction 
Over the last three decades HIV has become a worldwide epidemic that has 
claimed the lives of millions of people, and more people are currently living with the 
infection. As of 2011, the World Health Organization estimated that 34 million people 
were infected with HIV, and 2.5 million new infections occurred during the previous 
year (100). Additionally, a total of 1.7 million people died from AIDS associated 
infections in 2011 (100). 
The highest burden of HIV infection is on the continent of Africa where, in 
2011, UNAIDS estimated that over 23 million people were infected with HIV, which is 
more than the rest of the world combined (93). Furthermore, HIV is the number one 
cause of death in Africa. Although the prevalence of HIV in high-income countries is 
significantly less than in low- to middle-income countries, it is still a significant 
problem. Approximately 1.4 million people are infected with HIV in North America. In 
the United States, most new infections are occurring in young adults between the 
ages of 20 and 30 (15). The most common route of HIV transmission is through men 
having sex with men followed by heterosexual intercourse. However, the age group 
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that comprises the highest number of people living with HIV in the United States is 
between 45-54, which is likely due to a population of infected individuals that were 
infected during the initial outbreak and are now aging due to the availability of ART. 
In the United States, minority communities are disproportionally affected by HIV with 
an estimated 47% of new infections occurring in the African American population in 
the United States in 2010 (15). Both in the United States and worldwide, HIV is a 
significant public-health challenge. 
Transmission of HIV 
 HIV-1 is transmitted through contact of bodily fluids between infected and 
uninfected persons. The majority of infections occur through sexual contact or 
through needle sharing during drug use (15). A small number of infections occur due 
to transmission from HIV-infected mothers to their infants in utero, during birth, or 
later through breast-feeding. However, a combination of providing pre-natal 
prophylaxis and formula can reduce the rate of infant infections to less than 2% in 
some hospitals (24). In the past, there were instances where people were infected 
through blood transfusions. However, increased screening of blood products has 
effectively eliminated new infections through blood transfusions. Overall, the majority 
of preventable new infections occur through sexual contact.   
HIV-1 infection 
 HIV-1 primarily infects cells of the immune system that express CD4 on their 
surface and also have the co-receptors CCR5 or CXCR4, which include T cells, 
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macrophages, and a few other subsets that have recently been defined. CD4+ T 
cells have many roles in the immune system and differentiate into several lineages. 
One of the primary roles of T cells is in the response of the immune system to 
bacterial infection. CD4+ T cells help fight bacterial infection by binding to MHC 
class II molecules on the surface of antigen presenting cells that are presenting 
bacterial peptides and stimulating fusion of the vesicles and lysosomes within the 
infected cell to destroy the bacteria (48). Additionally, when CD4+ T cells recognize 
their target antigens on B cells, they stimulate the B cells to proliferate and produce 
antibodies. Antibodies that are specific for a pathogen can protect the host from 
infection either by coating the pathogen and preventing it from being able to attach 
to and infect cells or by targeting the pathogen for destruction by macrophages (48). 
Depletion of the CD4+ T cells results in severe immune depression and leaves the 
host susceptible to infection. 
 Macrophages and dendritic cells are both antigen-presenting cells, which 
means that they sample the environment for infectious agents, break them down and 
display foreign peptides on their cell surface to alert the immune system to infection. 
Macrophages are located throughout the body in the various tissues where they 
remove foreign microorganisms by phagocytosis (48). Additionally, macrophages 
clear cell debris from cells that have undergone apoptosis. Macrophages can also 
secrete signaling peptides that recruit immune cells to the site of infection. Dendritic 
cells are located in tissues that come in contact with the external environment such 
as the nose, lung, stomach and intestines. Dendritic cells sample their environment 
for potentially infectious microbes by phagocytosing large amounts of particulate 
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matter and displaying the contents on their surface for recognition by T cells (48). 
Both macrophages and dendritic cells are antigen-presenting cells that display class 
II MHC molecules to activate helper T cells. Although macrophages and dendritic 
cells are susceptible to HIV-1 infection, they have a limited amount of CD4 on their 
cell surface and it is unclear how commonly they are infected by HIV-1 in vivo. 
Soon after infection with HIV-1, the number of CD4+ T cells undergoes a 
drastic reduction that corresponds to an initial peak in viremia. At this stage, patients 
experience symptoms similar to a cold and sometimes have enlarged lymph nodes. 
After the initial peak in viremia, the CD4+ T cell counts stabilize as the host’s 
immune system attains a level of control. This stage of the disease is referred to as 
the asymptomatic period. Patients typically remain in the asymptomatic period for 
between two to twelve years. New guidelines suggest that ART be offered to all HIV-
1 infected patients regardless of their infection status and CD4+ T cell counts (92). 
The current recommendations indicate that the patient should remain on ART 
indefinitely (92). The transmitted virus is generally able to use the CCR5 chemokine 
receptor as a co-receptor for viral entry, which is referred to as being CCR5 trophic. 
However, virus that is able to use the CXCR4 co-receptor has the ability to be 
transmitted but is only transmitted rarely. In patients that are infected with CCR5 
trophic virus, as the disease progresses, new HIV-1 virions emerge with the ability to 
use the CXCR4 co-receptor (29). As HIV-1 infection progresses, the number of 
CD4+ T cells continues to decline and severe immune suppression develops. At this 
point, patients begin to develop opportunistic infections and are considered to have 
acquired immunodeficiency syndrome (AIDS). The immune suppression caused by 
 21 
HIV-1 infection does not directly cause mortality in the patients. Opportunistic 
infections that do not commonly cause significant disease in immune competent 
individuals are significantly worse in patients whose immune systems are 
compromised due to HIV-1 infection and can lead to mortality if they are not treated. 
Opportunistic infections that are prevalent in patients that have progressed to AIDS 
in high-income countries are thrush, pneumonia, cervical cancer, infection with 
mycobacterium and infection with cytomegalovirus (12). Tuberculosis, infection with 
enteric parasites, pneumonia and malaria are common opportunistic infections in 
regions were they are prevalent, and tuberculosis is the number one cause of death 
in HIV-1 infected patients in Africa. The inability of the immune system to combat 
opportunistic infections that are generally innocuous to immune competent 
individuals eventually causes mortality due to those infections.  
During the early years of ART, HIV-1 developed resistance to many of the 
drugs that were first developed as they were used singly or in pairs. Since the 
introduction of combination therapies, the development of resistance has become 
less of a problem. However, transmission of resistant species may limit therapy 
options for some patients. 
Prevention of HIV-1 infection 
During the last two decades, the number of new HIV-1 infections has 
significantly decreased due to many factors including campaigns to educate the 
public on how to prevent transmission of the virus (65). However, many new 
infections still occur each year. Recently, a great deal of focus has been on 
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developing additional prophylactic methods to prevent transmission of HIV-1. Cohen 
et al. found that treating the infected patient with ART significantly decreased the 
rate of transmission to their partner (19). Another study by Karim et al. in which they 
tested intravaginal gels containing the anti-retroviral drug Tenofovir demonstrated a 
39% reduction in HIV-1 acquisition (1). Condoms have traditionally been a very 
effective means of preventing new infections; however, in many cultures and 
relationships, placing the burden/responsibility of prevention on the male in the 
relationship has been unsuccessful. Developing tools to allow women to control their 
exposure risk is essential. Trials like the early treatment study and the intravaginal 
tenofovir study mentioned above are a positive step toward helping women to gain 
control over their own sexual health. However, neither of these studies had a 100% 
efficacy rate, and it is impractical and possibly unethical to ask people to rely on 
prevention methods that are not completely protective. 
Anti-retroviral therapy 
Currently, there is no cure for HIV-1 infection. However, ART is able to extend 
the life span of infected individuals to near that of non-infected individuals (96). Yet, 
ART is not a complete resolution to the epidemic for several reasons, the primary 
reason being that the quality of life for patients that are on ART is significantly 
affected. The associated adverse effects of the regimens are numerous and include 
diarrhea, nausea, rash, depression and headaches (44). Furthermore, the stigma 
associated with HIV-1 infection can be socially isolating. In addition to affecting the 
quality of life, another downside of ART is that the cost of these drugs is extremely 
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high. A typical month of first line ART in 2006 cost $1,140, and fourth line drugs cost 
upwards of $3,700 a month (84). Furthermore, current guidelines recommend that 
patients continue therapy indefinitely. The average life expectancy of patients after 
beginning ART is 24.7 years (84). In total, with doctors visits, tests and ART the 
lifetime cost of HIV-1 is upwards of $380,000 per patient (84). Although the 
advances in treatment of HIV-1 have significantly increased the quality of life for 
patients there is still significant room for improvement.  
In countries with patent law, to access drugs that cost less, patients generally 
have to wait 20 years until the drug is no longer protected by patent law. 
Furthermore, the trade-off is that the older drugs have more associated adverse 
effect and many strains of HIV-1 have developed resistance to these drugs. 
Although these drugs can reduce the cost of treatment, the disadvantages are still 
significant. 
In recent years, significant efforts have been made by several countries and 
organizations to provide anti-retroviral treatment to HIV-1 infected individuals in low- 
and middle-income countries. According to the World Health Organization 54% of 
people in low- and middle-income countries now have access to ART (99). However, 
there is still a significant need for additional access. In addition to the financial 
restraints, the physical access to a medical facility to obtain the ART and the social 
stigma associated with taking it prevents many people from getting the treatment 
they need. Furthermore, the economic burden of providing these drugs is largely 
shouldered by developed countries that are currently struggling with their own 
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economic crises. Therefore, providing ART to these countries may not be feasible or 
sustainable for the long-term.  
 Efforts to develop new therapies are being pursued (and to a large extent 
have been successful) that would have to be taken less often, are less susceptible to 
the development of resistance and that have fewer adverse effects (44). However, 
several downsides to the development of new therapies exist. Like current regimens, 
new therapies would have to be taken for the rest of the patient’s life. Although many 
of the newer drugs have fewer adverse effects, the associated adverse effects, both 
short term and long term, are still a concern (44). One of the most alarming aspects 
for the development of new drugs is that the cost is still significant, sometimes more 
than the current regimens. Therefore, the development of new therapies for HIV-1 is 
a good intermediate strategy, but is not a suitable approach for long-term 
management of the epidemic. Furthermore, studies such as the Cohen et al. study, 
which revealed a significant decrease in the transmission of HIV-1 in couples in 
which the index patient was taking ART have opened the discussion regarding how 
early ART should be initiated (19). Initiating ART earlier would significantly increase 
the cost and prolong the exposure of patients to the adverse effects that are 
associated with therapy. 
HIV-1 vaccine 
A significant amount of effort has been put into the development of a vaccine 
for HIV-1. However, even the most successful trial, RV144, only saw an efficacy of 
31.2% (79). Follow-up studies found that while that vaccine used in the RV144 trial 
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generated IgG antibodies against the variable regions 1 and 2 of envelope, IgA 
antibodies were also produced that may have diminished the effect of the IgG 
antibodies (45). As in the RV144 trail, the reasons for the lack of protection of many 
of the vaccines that have been developed are complicated. One of the primary 
reasons that development of a vaccine for HIV-1 has been difficult is the high 
genetic variability of HIV-1 populations. Successful design of an antibody-based 
vaccine may require the identification of an epitope that is broadly neutralizing 
across several HIV-1 clades. The morphology of the Env trimer and the genetic 
variability of HIV-1 make the development of such an antibody difficult. Regions of 
Env that are highly immunogenic are sequestered in the trimer, making them 
inaccessible to antibodies. Furthermore, due to conformational changes, antibody 
targets on gp120 can become inaccessible following binding to CD4. Furthermore, 
many antibodies target the variable regions of Env, which are highly glycosylated, 
and a simple mutation that results in the loss or addition of a glycosylation site can 
prevent binding of antibodies (47). Vaccine technology is continually improving and 
an effective vaccine may be developed in the future. While a vaccine would be a 
huge contribution to preventing new HIV-1 infections, it would not address the needs 
of people that are already of infected with HIV-1. Therefore, it is important to pursue 
additional strategies in conjunction with vaccine research.  
Latent HIV-1  
 Each of the above strategies to control HIV-1 is important and has 
significantly influenced the epidemic. However, none is completely efficacious, cost-
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effective or without limitations. Recently, a substantial amount of effort has been 
directed toward developing a short-term therapy that would eliminate all replication 
competent virus from infected individuals. Following such an eradication therapy, 
some remnants of defective proviruses may still be detectable in patients. Such a 
sterilizing cure would address many of the shortcomings of the above-mentioned 
approaches. The quality of life of the patients would be significantly improved over 
current ART regimens because they would not have to endure the ART-associated 
adverse effects. The cost of treatment to eliminate the virus would be limited to the 
duration of therapy. Furthermore, individuals that are in situations where they are 
unable to control their exposure would not have to endure a life-long infection. 
Overall, a cure would be the best solution for communities, patients and health care 
providers. 
Before moving on to how an effective cure for HIV-1 would be achieved it is 
important to explain why the current ARTs are not curative. Over the years since the 
beginning of the epidemic many therapies targeting different stages of the HIV-1 
replication cycle have been developed including drugs that target entry, reverse 
transcription, integration, and protease cleavage. These therapies are very effective 
at inhibiting HIV-1 replication. In fact, patients that are faithfully taking ART and have 
not developed resistance have viral loads that are undetectable by standard 
methods for many years. However, a very small population of HIV-1 infected cells 
remain. The majority of this latent virus resides in the CD4+ resting memory T cells 
of the immune system. Other reservoirs have been suggested to exist in the brain, 
gut-associated lymphoid tissue, bone marrow, and genital tract (14). Furthermore, 
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additional undiscovered reservoirs may also exist, and studies to elucidate these 
reservoirs are currently underway. Cells are considered to harbor latent virus when 
the virus has entered the cell, reverse transcribed its viral RNA into a DNA copy and 
inserted its DNA provirus into the host cell’s genome; instead of continuing through 
the replication cycle, the proviral genome becomes transcriptionally silent. These 
transcriptionally silent but replication competent viral genomes can collectively be 
referred to as quiescent or latent proviruses, meaning that they are not making viral 
proteins or full length RNA, which would be required for the virus to continue through 
the replication cycle. Unfortunately, these viral genomes are virtually 
indistinguishable from the genome of the host and are therefore very difficult to 
target. Virus that is not going through the stages of the replication cycle that are 
targeted by ART are resistant to treatment with current regimens. If the virus were to 
remain in this state indefinitely, it would not be a problem for patients. However, the 
virus has the ability to spontaneously and unpredictably resume transcription and if 
the patient is not on ART, the virus can resume replication and renew infection. 
Therefore, patients must remain on ART indefinitely to control spontaneous 
reactivation of these transcriptionally silent viruses. 
 Until recently, few researchers were in serious pursuit of strategies to cure 
HIV-1 infection, but this effort has recently gained widespread acceptance and 
attention. Because of this, many novel strategies have been proposed to 
complement traditional drug therapies. However, regardless of the approach, not all 
therapies are created equal. Indeed, for a therapy to be effective and feasible for 
worldwide use, it will have to meet several requirements. First and most importantly, 
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the therapy must be safe and have manageable side effects. Second, it must not 
extensively activate the immune system, as activated T cells are more susceptible to 
HIV-1 infection and are more difficult to protect with ART. Third, the treatment must 
have a finite duration that will allow the patient to live a healthy life without the need 
for ongoing treatment. Fourth, if the goal is eradication, the treatment must be able 
to access all reservoirs of persistent infection throughout the body. Finally, to ensure 
global utility and availability, the therapy must be economically and logistically 
accessible to the developing world, as this is where the burden of lifelong therapy is 
least sustainable. Initially, drugs that have already been pharmacologically 
characterized and approved for use in humans for treatment of other diseases will 
have an advantage over newer approaches, as the time from initial testing to 
implementation will be drastically reduced. That said, many novel approaches to 
treating HIV-1 infection, some of which are detailed below, are receiving a great deal 
of attention from the research community and may prove invaluable in our pursuit of 
a cure.  
HIV-1 eradication strategies 
Eradication is what most often comes to mind when people think about a 
“cure” for HIV-1. The goal of this approach is clearance of all replication competent 
virus from the patient. Purging HIV-1 provirus from latent reservoirs is crucial to any 
HIV-1 eradication strategy, and interest in this area has spurred major efforts to 
identify therapeutics that can do so. Most eradication studies have focused on 
identifying small molecule drugs that elicit proviral expression with the notion that 
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ART will prevent new infections while the immune system, possibly with the help of 
other therapeutics, will clear infected cells. Indeed, several small molecule drugs that 
have been developed for the treatment of HIV-1 latency are currently in clinical trials 
(table 1). Beyond these drugs, other conceptual options for eradication include gene 
therapy approaches such as HIV-1-specific recombinases that destroy proviral DNA 
or HIV-1-dependent suicide genes that selectively kill HIV-1-infected cells. 
The human immunodeficiency virus  
 To understand how a cure could possibly be achieved, it is important to first 
understand more about HIV-1 and its replication cycle. HIV-1 is a positive stranded 
enveloped RNA virus in the family Retroviridae and the genus lentivirus. The HIV-1 
genome encodes the core proteins (Gag, Pro, Pol, and Env), two regulatory proteins 
(Tat and Rev), and four auxillary proteins (Nef, Vif, Vpu, and Vpr) (33).  
The HIV-1 virion initially makes contact with the target host cells by binding to 
the CD4 receptor and either the CCR4 or CXCR5 co-receptors on the cell surface. 
The viral gene env codes for the HIV-1 glycoproteins gp41 and gp120, which bind to 
CD4 and the CCR5 and CXCR4 co-receptors and facilitate viral entry (102).  The 
polyprotein Pol encodes several proteins that are important for many stages of the 
viral replication cycle including protease, reverse transcriptase, RNase H and 
Integrase. Pol is cleaved into its components by protease, which also cleaves the 
Env and Gag polyproteins in to their individual viral proteins, which will be discussed 
later during the discussion of maturation of the virions (46, 60). After the virus has 
bound to the receptors and fused with the cell, one of the two RNA genomes is 
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reverse transcribed by viral Reverse Transcriptase (RT), which creates a double-
stranded DNA proviral genome from the genomic RNA. During this process an 
RNA/DNA intermediate product is briefly produced that is composed of the genomic 
RNA and the first strand of the DNA provirus. The viral protein RNase H quickly 
degrades the RNA in this hybrid to allow the second strand of DNA to be 
synthesized (86). Following synthesis, the pre-integration complex, which contains 
the HIV-1 provirus, is shuttled into the nucleus where it integrates into the host’s 
DNA. The ability of the HIV-1 pre-integration complex to enter the nucleus allows 
HIV-1 to infect non-dividing cells (32). Once the proviral DNA is integrated into the 
host’s genome the integrated provirus serves as a transcription template for viral 
RNAs. The viral protein Tat, through its interaction with pTEF-b, is a potent activator 
of HIV-1 transcription. HIV-1 transcripts contain several splice donor and acceptor 
sites that are recognized and cleaved by the cellular splicing machinery. The initial 
viral RNAs are fully spliced and produce the early proteins such as Tat, Nef and 
Rev. However, HIV-1 also needs to produce partially spliced and full-length genomic 
RNA. The viral protein Rev binds to unspliced or partially spliced HIV-1 RNA and 
facilitates their nuclear export (32). The Gag polyprotein is cleaved during virion 
maturation into its individual components that include matrix (MA), capsid (CA), 
nucleocapsid (NC) and p6, which are important for the assembly and budding of new 
viruses. The matrix protein is important for localization of the Gag polyprotein to the 
cell membrane where the virus assembles prior to budding from the cell (32). Once 
the virus buds from the cell, it undergoes further maturation through proteolytic 
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cleavage of Gag-Pro-Pol into its constitutive components, which facilitates 
condensation of NC-RNA and maturation of the CA core (60). 
The final viral particle has many components including a conical shaped viral 
core that is composed of the capsid protein, RT and two copies of the genomic RNA, 
which is bound to nucleocapsid to facilitate encapsidation into the virion (31). 
Nucleocapsid accelerates reverse transcription by facilitating binding of the R 
sequence of the ss-cDNA region to tar during the transfer of the first strand (23, 39). 
The viral protein p6 is involved in budding of the virus from cells and in incorporation 
of Vif and VPR into the virion (40).  
Retroviruses have been around for thousands of years. In fact, a large 
percentage of the human genome is composed of remnants of retroviruses called 
retroelements (25). Over time, human cells have evolved protective mechanisms to 
defend themselves from retroviruses including TRIM5!, Tetherin and APOBEC3G. 
TRIM5! is a cellular protein that interacts with the capsid protein and accelerates 
decoating of the virus, which results in an unstable viral core that is unable to 
advance through the HIV replication cycle (91). Tetherin is another host factor that is 
restrictive to HIV-1. Tetherin homodimers are located in lipid rafts in the cellular 
membrane. When HIV-1 buds from the cell, regions of the tetherin protein are 
embedded in the membrane of the budding virus and in the membrane of the cell, 
which effectively tethers the virion to the cell and prevents budding (110). 
APOBEC3G is a DNA cytosine deaminase that is packaged into HIV-1 virions and is 
able to mutate HIV-1 DNA during subsequent infection as it is being reverse 
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transcribed (105). HIV-1 encodes the Vif accessory protein, which counteracts the 
cellular factor APOBEC3G (87). Vif binds to and promotes degradation of the cellular 
antiviral protein APOBEC3G (69). Viruses that lack Vif are susceptible to mutation 
and inactivation by APOBEC3G.  
 Another accessory protein, Vpr is involved in many processes during the 
HIV-1 replication cycle from induction of HIV-1 transcription to nuclear import of the 
HIV-1 pre-integration complex. However, the most well-known function of Vpr is its 
ability to arrest cells in the G2 phase of the cell cycle, which is important for the early 
stages of HIV-1 infection (41, 56). The Vpu protein binds to and induces degradation 
of the CD4 protein and is involved in release of viral particles from the cellular 
membrane. Nef induces the degradation of several cellular proteins including MHC-1 
and CD4, which prevents superinfection and interferes with the ability of the immune 
system to control infection (2, 8). Additionally, Nef is important for the pathogenicity 
of HIV-1, which was most elegantly demonstrated by the Sydney blood bank cohort 
of HIV-1 infected patients who were infected with a virus containing a deletion in Nef 
and remained asymptomatic for over 15 years (28, 34). The many virally encoded 
proteins interact with cellular proteins to facilitate successful replication of HIV-1. 
Several noncoding regulatory regions including the Trans-Activating 
Response element (TAR) and the Rev Response Element (RRE) are important parts 
of the HIV-1 genome. As the proviral genome is transcribed, a secondary structure 
called TAR forms toward the beginning of the elongating RNA that is able to bind the 
viral protein Tat (7). Tat in turn recruits pTEF-b, which phosphorylates the C-terminal 
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tail of RNA pol II and promotes transcriptional elongation (66). The RRE is another 
non-coding region that is very important for HIV-1 replication. The RRE is 
recognized by the viral protein Rev, which facilitates nuclear export of partially 
spliced and unspliced genomic RNAs (78). Partially spliced RNAs are important for 
translation of Env, Vpu, Vpr, and Vif. The non-coding regions TAR and RRE are 
involved in many steps of the HIV-1 replication cycle. 
One of the most important non-coding regions of HIV-1 is the long terminal 
repeat (LTR) or the promoter. The LTR controls viral transcription and is thought to 
mediate the development of HIV-1 latency. During HIV-1 replication, transcription is 
very robust. However, occasionally, the long terminal repeat becomes occupied by 
repressive transcription factors that inhibit transcription from the viral promoter (95). 
When viral mRNAs are not transcribed or viral proteins not translated, infected cells 
are not detectable by the immune system and the provirus is not susceptible to ART. 
The long terminal repeat has been extensively characterized and can be occupied 
by many transcription factors including c-Myc, YY1, NF-"B and CBF-1 (21, 49, 67, 
104). Many of these factors have been demonstrated to both positively and 
negatively regulate transcription depending on the context of the promoter. 
Furthermore, c-Myc, YY1, NF-"b and CBF-1 have all been shown to be important for 
recruitment of Histone deacetylase 1 (HDAC1) to the HIV-1 LTR in many different 
contexts (21, 49). The restriction of transcription at the HIV-1 promoter due to the 
development of heterochromatin is thought to play an important role in the 
maintenance of the quiescent proviral state.  
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Establishment of Latency 
 Occupancy of the LTR by the repressive factors discussed in the previous 
section is thought to maintain latency. However, how latency initially develops is still 
somewhat debatable. Several mechanisms have been proposed for the 
establishment of the quiescent proviruses. One theory is that as the infected active 
CD4+ T cell transitions to the resting state the availability of factors that are required 
for transcription become limited within the cell and are not available at the HIV-1 
promoter (59). Other experts believe that latency may be a random state that is 
established in active CD4+ T cells that become long lived resting CD4+ T cells. The 
site of viral integration may also affect the development of latency. Studies have 
shown that HIV-1 preferentially integrates into actively transcribing genes (42). 
Insertion downstream of an active promoter may inhibit the ability of the HIV-1 
genome to initiate transcription due to interference by active transcriptional 
machinery from the upstream promoter (43). Additionally, although HIV-1 genomes 
favor sites of active transcription, it is still possible for them to insert into sites that 
contain heterochromatin, which can restrict access of transcription factors to the 
promoter (64). Others have proposed that some HIV-1 latency may be due to the 
persistence of pre-integration complexes in cells. However, research has indicated 
that these pre-integrated complexes have a half-life of approximately one day and 
therefore may not account for a significant amount of the replication latency found in 
patients (111). It is currently unknown which of these mechanisms are primarily 
responsible for the majority of latent HIV-1. It is likely, however, that all of the above 
mechanisms may contribute to maintenance of the quiescent proviral pool.   
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HIV-1 persistence 
 The mechanism of maintenance of the latent reservoir has also been 
debated. Some believe that there is a low level of ongoing replication in patients that 
are on suppressive HAART that continually reseeds the latent viral reservoir (109). 
However, studies looking at evolution of virus do not see any evidence of viral 
evolution, which indicates that the viruses are not replicating (74). Therefore, some 
have proposed that the latent population may be maintained by replication and 
clonal expansion of infected cells (88). Others believe that there may be pockets of 
infected cells that occasionally reseed the viral reservoir (52, 88). Eventually, it may 
be necessary to determine which of these scenarios most accurately mimics the in 
vivo state to tailor latency treatments. 
Models for the study of latent HIV-1 
Lack of a truly representative model system is a significant obstacle to HIV-1 
latency research. Currently, the best model is the cells of aviremic patients. The gold 
standard for monitoring the effectiveness of small molecules on inducing viral 
production is the patient cell assay, which is labor, time and resource intensive (18). 
Many important research goals cannot be achieved using human cells due to 
technological or ethical restraints. Furthermore, access to latently infected patient 
cells is limited. SIV models are available, but are expensive and do not accurately 
represent the latent state in humans. Humanized mouse models have been 
developed for latency (16). These models are relatively new, but may prove to be a 
good system to screen therapies in prior to introduction into humans. So far, our lab 
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and Dr. Victor Garcia’s lab have been able to stably suppress viral infection in 
humanized mice using ART (16, 26). The next step in this model will be to test the 
induction and clearance strategies by administering HDAC inhibitors or other 
compounds that activate HIV-1 transcription in the presence of ART and by 
monitoring the percentage of latently infected cells.  
For many years, cell line models of HIV-1 latency have been the workhorses 
of the field. Initially, many HeLa cell lines carrying HIV-1 LTRs with a reporter were 
used (50, 54, 58, 82). More recently, several Jurkat, monocytic and glial cell lines 
have been developed that contain full-length HIV-1 genomes with a reporter inserted 
into the genome to facilitate detection of transcription from the viral promoter (111). 
Jurkat cells are derived from T lymphocytes, which are the target cells of in vivo 
infection. These cell lines have been very useful for the careful characterization of 
the range of factors that bind to the HIV-1 LTR, and preliminary studies on small 
molecules and their ability to induce transcription from the HIV-1 LTR (104). 
However, each cell line is a clone that has only one insertion site. In vivo the virus 
integrates randomly into each cell creating a diverse population of insertion sites that 
cannot be accurately mimicked by the current cell line models (85). Furthermore, the 
cell lines are composed of actively replicating cells, whereas resting memory T cells, 
where the majority of latent virus is thought to exist, are in a quiescent state. Several 
of these lines are available, but alone none are truly representative of the in vivo 
environment where there are many different insertion sites and little cellular 
replication. However, cell lines have proven to be a good starting point to test the 
effectiveness of compounds prior to moving them to the patient cell assays. 
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Recently, several labs have developed primary cell models of latency where CD4+ T 
cells are isolated from uninfected donors and subsequently infected with HIV-1 and 
allowed to enter a resting state (10, 83). These models mirror the range of insertion 
sites that are observed in vivo and the non-dividing phenotype of resting memory 
CD4+ T cells. Therefore, labs are now incorporating use of one or more of these 
models into their research. 
HDAC inhibitors as inducers of latent HIV-1 
Histone deacetylase inhibitors (HDACis) were identified as candidate anti-
latency drugs following the discovery that their target HDACs were specifically 
recruited to the HIV-1 promoter and maintained latency (51, 94). Corroborating this, 
HDACi were identified in several screens for compounds that induce transcription 
from quiescent HIV-1 proviruses (57). While HDACs might be better termed lysine 
deacetylases, as they can remove acetyl groups from both histone and non-histone 
proteins, their removal of acetyl groups from the lysine residues within histone tails is 
associated with reduced transcription from cellular and viral promoters. Inhibition of 
HDACs allows histone lysine acetylation to persist, which then results in recruitment 
of transcriptional activators and facilitates transcription from the HIV-1 promoter 
(Figure 1.1). Suberoylanilide hydroxamic acid (SAHA) and valproic acid (VPA) are 
HDACis that activate HIV-1 transcription in both cell line models of latent HIV-1 and 
in ex vivo cultured patient cells. Both drugs are currently approved for clinical use, 
SAHA for oncology and VPA for a variety of indications, and many of their 
pharmacological characteristics are known. HIV-1-centered clinical trials have been 
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conducted for VPA, and two such clinical trials are ongoing for SAHA (4, 61). Past 
studies testing VPA using varying designs and endpoints have had mixed results, 
but uniform and exposure-dependent depletion of the latent viral reservoir has not 
been observed (61, 89). Recent work suggests that alternative HDACis, such as 
SAHA, are able to induce expression from the HIV-1 promoter at lower 
concentrations than VPA (70). Notably, the initial results from the SAHA clinical trials 
are promising. In a trial being conducted by our group, HIV-1-positive patients were 
given a 400 mg dose of SAHA and resting CD4+ T cells were isolated to measure 
viral RNA production and global histone H3 acetylation to determine whether SAHA 
is able to upregulate viral transcription. To date, all patients in the study have 
demonstrated increased viral RNA production and histone H3 acetylation, which 
indicates that HIV-1 latency was disrupted following a single 400 mg dose of SAHA 
(clinical trial NCT01319383) (Table 1)(4). A second study at Monash University in 
Melbourne is underway to assess a multi-does regimen of SAHA administered as 
400 mg of SAHA daily for 14 days (Table 1) (63). The results from this trial are 
currently pending. If the results from these studies verify the ability of SAHA to 
activate quiescent HIV-1 in patients, the next step will be to determine whether this 
activation has an effect on the viral reservoir.  
 In addition to SAHA and VPA, several additional HDACis that activate 
transcription of quiescent proviruses including Belinostat, Panobinostat, Givinostat, 
and Entinostat, are currently in phase II clinical trials for treatment of cancers or 
juvenile arthritis (70, 101). Furthermore, a clinical trial for juvenile arthritis in which 
children ranging from 6-17 years of age were administered daily Givinostat revealed 
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only minor adverse drug effects, suggesting the drug’s potential utility for treating 
youth and adolescents (98). In addition to activation of HIV-1, Givinostat and SAHA 
have also been demonstrated to transiently reduce expression of a subset of 
cytokines at a clinically relevant dose in ex vivo studies (37, 62). Because activating 
the inflammatory response may activate the immune system, making cells 
susceptible to HIV-1 infection, suppression of the inflammatory response may 
prevent infection of additional cells upon reactivation. Depending upon the safety of 
these drugs and their pharmacological suitability, these drugs may also be tested in 
future clinical trials addressing HIV-1 latency. 
Conceptually, it is important to note that the most desirable qualities of the 
ideal HDACi for clinical application in HIV-1 remains to be defined. Obviously, such a 
drug must be clinically well tolerated. Current evidence suggests that inhibitors 
selective for the Class I HDACs 1, 2, and 3 are the most relevant (5, 51), and recent 
studies suggest that HDAC3 may be the most important target. However, highly 
selective inhibitors for HDAC3 are only recently available. Although it is widely 
assumed that a more potent HDAC inhibitor will have a better clinical effect, this is 
unproven. Of central importance, the optimal duration and schedule for dosing that is 
required to achieve sufficient HIV-1 induction without impairing the immune 
response or inducing toxicity is unknown. 
Disulfiram 
 Disulfiram is a zinc-chelating agent that is approved for use in humans to treat 
alcoholism. Its toxicities are managable. Dilsulfiram and its metabolite 
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diethyldithiocarbamate (DDTC) were recently demonstrated to activate HIV 
transcription from a primary cell model of latent HIV (107). A study by Doyon and 
colleagues suggests that disulfiram causes depletion of Phosphatase and tensin 
homolog (PTEN), which is an inhibitor of the Akt pathway. Once inhibition of Akt is 
removed it phosphorylates HEXIM1, which releases p-TEFb. Free p-TEFb is then 
recruited to the HIV promoter were it can activate transcription (Figure 1.1). In further 
support of this model, dilsulfiram mediated activation of quiescent HIV proviruses 
was blocked by an inhibitor of the Akt pathway, which indicates that disulfiram may 
modulate HIV expression through its effects on PTEN and the Akt pathway (27). A 
clinical trial (NCT01286259) with dilsulfiram has been undertaken to determine its 
effect on persistent HIV infection in patients. The pilot study enrolled 14 participants 
who took 500 mg of disulfiram daily for 14 days (Table 1). The initial results from the 
pilot study revealed a modest but statistically significant increase in plasma HIV RNA 
in the group as a whole, largely driven by transient and temporally dispersed 
increases in viral load in only a few patients and a minimal absolute decrease in the 
frequency of infected resting CD4+ T cells that was within the range of variation 
seen in viral outgrowth assays (90). At this time, it is unclear if disulfiram can 
contribute to clinically significant reductions in the viral reservoir. 
PD-1 inhibition 
 PD-1, which is a receptor that is best known for its role in immune exhaustion, 
is currently the focus of several studies aimed at treating latent HIV. PD-1 antibodies 
are being investigated for their ability to activate HIV transcription and/or reverse 
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immune exhaustion caused by HIV infection while specifically targeting HIV infected 
cells. To date, a single abstract has been presented, which suggests that exposure 
to PD-1 antibodies induces expression of HIV. However, the relevance and validity 
of this observation was weakened by the fact that the cells studied were obtained 
from viremic patients (22). A clinical trial in development to determine the effect of 
PD-1 antibodies on persistent infection in ART-treated patients is currently delayed 
by unanswered safety concerns arising from observed toxicities following the use of 
the drug in oncology trials (Table 1).    
Vaccination 
Several studies have reported increases in viral expression following routine 
vaccination against other pathogens in HIV-infected individuals, which may be 
attributable to mild activation of the immune system (13). However, the increased 
viral loads and T cell activation after immunization were not associated with better 
viral control when ART was interrupted (13), indicating that this therapy may need to 
be performed in the context of ART or other therapeutics. In an interesting and 
provocative study, Persaud and colleagues immunized patients with a poxvirus 
vaccine engineered to express HIV antigens and observed a significant, albeit 
transient, decrease in replication-competent HIV in the resting T cell reservoir (Table 
1) (77). These results suggest that such approaches might activate latent virus 
and/or induce an immune response to low-level antigen production in some cells, 
thereby resulting in a decline of the number of latently infected T cells. Such 
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vaccines have been studied and well tolerated in HIV infected patients, and so this 
strategy has potential for use in treating latent HIV (38).  
Other potential targets 
While HDACis are currently the most promising candidates for the “kick and 
kill” approach, many other cellular pathways are involved in the maintenance of 
latent HIV, and compounds targeting these pathways may enter clinical trials in the 
near future. Here, we briefly discuss examples of these pathways and a few of the 
promising compounds under study. 
Activation of the protein kinase C (PKC) and NF-"B pathways induces 
expression of quiescent HIV proviruses. Once activated, PKC phosphorylates I"B!, 
which results in release of NF- "B. NF- "B then translocates to the nucleus where it 
binds to the HIV LTR and promotes transcriptional activation (Figure 1.1). Drugs 
targeting these pathways, such as tumor necrosis factor-alpha (TNF-!), prostratin, 
and bryostatin are currently under study for treatment of latent HIV infection (11, 75, 
103). Prostratin, a phorbol ester that targets both the PKC and NF- "B pathways, 
activates HIV transcription in several J-lat cell line models of HIV latency (103). 
Additionally, prostratin in combination with the HDACis VPA and SAHA 
synergistically increases the amount of virus produced from cell line models of HIV 
latency (80). Bryostatin, a macrocyclic lactone, is another candidate that targets the 
PKC and NF-"B pathways. In addition to modulating the PKC and NF-"B pathways, 
bryo-1 also downregulates the CD4 receptor on T cells, which limits the ability of HIV 
to infect these cells (Figure 1.1) (11). Importantly, Bryostatin does not activate T-
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cells and has low cytotoxicity (71). Bryostatin has entered a phase II clinical trial for 
treatment of ovarian cancer (73). However, in this trial, despite a partial response of 
some patients to the treatment, severe myalgia developed in all study participants 
(73). While studies to advance bryostatin for future treatment of latent HIV are 
planned, testing will have to be cautious in light of these side effects.  
Hexamethylene bisacetamide (HMBA), a modulator of the HMBA inducible 1 
(HEXIM1) component of the 7SK snRNP, also stimulates HIV transcription (17, 55). 
HMBA activates the PI3K/Akt pathway, resulting in HEXIM1 phosphorylation and 
release of the transcriptional elongation factor P-TEFb from the transcriptionally 
repressive 7SK snRNP/HEXIM complex (20). Following its release, P-TEFb is 
recruited to HIV TAR by HIV Tat, which facilitates productive transcription elongation 
(Figure 1.1). HMBA reached phase II clinical trials for acute myelogenous leukemia 
(3), and while the drug was tolerable in this setting, further studies have not been 
pursued due to lack of efficacy in cancer. HMBA was also rapidly metabolized, 
eventually requiring continuous IV infusion in studies to achieve detectable drug 
levels. Clinical trials for treatment of latent HIV have not been pursued. 
 In addition to histone deacetylation and signaling cascades, other possible 
targets for therapy are being investigated. Among these are enzymes that methylate 
histone proteins or DNA. Depending on the site of methylation and the number of 
methyl groups present, these modifications can recruit proteins that activate or 
repress transcription. 5-aza-2’-deoxycytidine (5-Aza-CdR), an inhibitor of DNA 
methyltransferases, activates transcription from the HIV LTR in several cell line 
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models of latent HIV (Figure 1.1)(30). Furthermore, several histone 
methyltransferases (HMTs), including SUV39, G9a, EZH2 among others, have been 
demonstrated to be involved in transcriptional modification of HIV (35). When the 
HIV promoter is in the quiescent state high levels of the repressive chromatin 
modifications trimethylated lysine 9 and lysine 27 of histone 3 and HP1-! can be 
detected at the HIV promoter by ChIP (76). Following induction of transcription from 
the HIV LTR using TNF-! the levels of trimethylated lysine 9 and lysine 27 of histone 
3 as well as the levels of associated HP1-! decrease. Significantly, the HMT 
inhibitors (HMTis) Chaetocin, BIX-01294 and DZNep reactivate HIV transcription in 
cell line models of HIV latency. However, the relevance of these observations to 
clinical applications remains unproven and awaits the assessment of these 
compounds in authentic resting cells from patients (35). Further, the clinical safety of 
these drugs has not been assessed outside of limited studies in advanced 
malignancies, and so the development and clinical validation of safe and effective 
HMTis and DNMTis remains an important research goal.  
Additional compounds that may relieve HIV latency are currently under 
investigation. Xing and colleagues conducted a drug library screen to identify 
compounds that activate HIV transcription in a primary cell model of HIV latency, 
and derivatives of quinolin-8-ol, a bivalent cation chelator, were identified (Figure 
1.1)(106). Furthermore, Micheva-Viteva and colleagues also performed a high 
throughput screen of 200,000 compounds on a lymphoid cell line model of HIV 
latency and found that AV6, a 4-3’, 4’-dichloroanilino-6-methoxyquinoline compound, 
was able to induce transcription of HIV (72). While the mechanisms of viral activation 
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are not known for these newly identified compounds, they did not significantly 
activate T cells. Thus, these new compounds represent additional classes of drugs 
that show potential as a treatment for latent HIV infection (72). 
Histone deacetylases 
As discussed in a previous section, small molecules that are able to inhibit 
HDACs are potent activators of transcription from quiescent proviruses in almost 
every model they have been tested in. Therefore, the role of histone deacetylases in 
establishment and maintenance of HIV-1 latency has been extensively 
characterized. The HDAC family of enzymes contains 11 different members that are 
divided into four classes (9). Class I is composed of HDAC1, HDAC2, HDAC3 and 
HDAC8. HDACs are lysine deacetylases that were originally identified as proteins 
that deacetylate the tails of histone proteins; however, several non-histone targets of 
HDACs have also been identified including the p65 subunit of NF-"b and CyclinT1 
(9), which is a component of p-TEFb (9, 53). Deacetylation of histone tails removes 
signals that recruit factors including bromodomain proteins and transcription factors 
that initiate transcription and elongation from the HIV-1 promoter. HDAC1, HDAC2, 
HDAC3 and HDAC8 make up the class I HDAC family. HDAC1 and HDAC2 are 85% 
homologous at the DNA sequence level, while HDAC3 only shares 52% and 53% 
similarity with HDAC1 and HDAC2, respectively (108). HDAC1 and HDAC2 are 
components of the Sin3, CoREST/REST, XFIM and the NuRD complexes (97), while 
HDAC3 is found in a separate complex, the NCoR/SMRT complex (97). HDAC3 has 
specifically been demonstrated to deacetylate two factors that are present at the 
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HIV-1 promoter in addition to histone tails, namely p65 and CyclinT1 (36, 53). Keedy 
et al. demonstrated that the HIV-1 long-terminal repeat is specifically occupied by 
HDAC1, HDAC2 and HDAC3 (51). Furthermore, Archin et al. demonstrated that 
small molecule inhibitors of HDAC1, HDAC2 and HDAC3 are potent inducers of 
transcription from the HIV-1 promoter, while inhibitors of HDAC1 and HDAC2 do not 
significantly activate transcription from the HIV-1 promoter (6), indicating that 
HDAC3 is required for HDAC inhibition mediated expression from the HIV-1 
promoter. However, these studies did not address whether HDAC3 was sufficient to 
induce transcription from the HIV-1 LTR. HDAC1 and HDAC3 transcripts are 
expressed at a four and eight log fold increase relative to an internal control gene in 
CD4+ T cells from patients, respectively, while HDAC2 is expressed to a lesser 
extent of approximately a one log fold increase over the internal control gene (51). 
Additionally, HDAC1, HDAC2 and HDAC3 proteins are detectable by Western blot in 
nuclear extracts of aviremic CD4+ patient cells (51).  
c-Myc  
HDACs do not contain DNA binding domains and must be recruited to 
promoters through association with local transcription factors. The lab has 
extensively characterized the recruitment and binding of two repressive transcription 
factors that associate with the HIV-1 LTR and HDACs, c-Myc and YY1. The lab 
initially became interested in c-Myc when it was detected in a screen to determine 
which mRNA transcript levels were affected by treatment with the HDAC inhibitor 
valproic acid (VPA) (49). The expression of c-Myc is significantly downregulated by 
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treatment with VPA in CD4+ T cells from aviremic patients (49). Furthermore, 
overexpression of c-Myc in HeLa cells inhibited the ability of Tat to induce 
transcription from the HIV-1 promoter (49). Additional investigation of cMyc revealed 
that it associates with the HIV-1 LTR through an interaction with Sp1 and that it 
interacts with HDAC1, suggesting a mechanism for its role in repression of HIV-1 
transcription (49).  
YY1 
Several studies have been performed demonstrating that YY1 binds to the 
HIV-1 LTR and represses HIV-1 transcription. YY1 is recruited to the HIV-1 LTR 
through an interaction with LSF (81). Overexpression of YY1 inhibited the basal level 
of expression from the HIV-1 promoter in a HeLa cell line containing an HIV-1 driven 
reporter (68); however, overexpression of LSF does not have an effect on HIV-1 
expression. Co-overexpression of LSF and YY1 significantly decreases basal 
transcription from the HIV-1 LTR (81). Later studies revealed that YY1 associates 
with and recruits HDAC1 to the HIV-1 promoter (21). These findings highlight the 
role of YY1 at the HIV-1 LTR. 
The following work was performed to further extend the previous findings 
regarding c-Myc and YY1 and recruitment of HDAC1 to the HIV-1 LTR and to 
determine whether c-Myc and YY1 also recruit HDAC2 and HDAC3 to the HIV-1 
promoter.  
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Selective targeting of HDACs to induce HIV-1 transcription 
This dissertation is focused on identifying targets for the induction and 
clearance method of disrupting latent HIV. When this project was initially started 
Keedy et al. had recently determined that of the 11 HDACs, HDAC1, HDAC2, and 
HDAC3 were specifically bound to the HIV-1 promoter. Furthermore, Archin et al. 
had found that HDAC inhibitors that target HDAC1, HDAC2, and HDAC3 were able 
to effectively induce transcription from quiescent viral promoters in cell line models 
of latent HIV-1 and in cells from infected, suppressed patients. These two important 
studies indicated that HDAC1, HDAC2 and HDAC3 were important for reactivation of 
quiescent HIV-1 proviruses. However, HDACs affect the expression of many cellular 
genes. Therefore, the goal of this project was to identify methods to specifically 
target transcription from the HIV-1 promoter. Previous work had determined that two 
transcription factors, cMyc and YY1, both repressed expression from the HIV-1 
promoter and that they were both important for recruitment of HDAC1 to the HIV-1 
promoter. Because of the high similarity between HDAC1, HDAC2, and HDAC3 and 
because HDAC1 and HDAC2 are found in several complexes together (97), the 
hypothesis for the first project in this dissertation was that cMyc and YY1 may recruit 
HDAC2 and HDAC3 to the HIV-1 promoter. Furthermore, targeting recruitment of 
cMyc or YY1 to the HIV-1 promoter may relieve HDAC mediated repression of viral 
transcription. While depletion of YY1 was sufficient to induce transcription from the 
HIV-1 promoter, it did not affect the occupancy of HDAC2 or HDAC3 at the HIV-1 
promoter. Furthermore, depletion of cMyc did not affect transcription from the HIV-1 
promoter in the Jurkat cell line models that were studied nor did it significantly affect 
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occupancy of HDAC2 or HDAC3. Therefore, redundant mechanisms at the HIV-1 
promoter may compensate for the loss of a single or subset of transcription factors.  
To follow up on the initial study, the goal of the second project was to 
determine whether targeting a single or subset of HDACs would be sufficient to 
induce transcription from the HIV-1 promoter. However, each of the HDACs control 
transcription from many cellular promoters. Therefore, it was reasonable to 
hypothesize that targeting only one or two of the HDACs may affect the transcription 
of fewer cellular genes. To determine whether targeting a subset of the HDACs was 
sufficient to relieve repression of the HIV-1 promoter shRNAs were used to deplete 
HDAC1, HDAC2, and HDAC3 individually or in combination. Depletion of HDAC1 or 
HDAC2 did not affect transcription from the HIV-1 promoter. Importantly, depletion of 
HDAC3 increased both protein and mRNA expression from the HIV-1 promoter, 
indicating that HDAC3 may be a potential therapeutic target for the treatment of 
latent HIV. 
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Figure 1.1. Induction and clearance strategies.  (I) Induction. Several small 
molecules have been identified that are able to induce transcription of quiescent 
HIV-1 proviruses. Prostratin, TNF-!, and bryostatin have been demonstrated to act 
on the PKC/NF-!B pathway. Activated protein kinase C (PKC) phosphorylates I"B! 
causing release of NF-!B. NF-!B then translocates to the nucleus where it binds to 
the promoter of HIV-1 and promotes transcription. HDAC inhibitors directly inhibit 
deactylation of histones at the HIV-1 LTR, which is associated with induction of 
transcription. Similarly, histone methyl transferase inhibitors (HMTi) inhibit the 
methylation of histone tails, which is associated with transcription from the HIV-1 
promoter in some model systems. HMBA causes activation of the Akt pathway, 
which may result in phosphorylation of HEXIM. This may result in the release of 
pTEF-b from the inhibitory HEXIM complex, allowing pTEF-b access to the HIV-1 
LTR where it phosphorylates RNA pol II and primes the LTR for transcription. 
Disulfiram has been shown to act upstream of HMBA, perhaps by causing 
degradation of PTEN, an inhibitor of AKT. Activated AKT then phosphorylates 
HEXIM and LTR induction ensues. Vaccination may activate some T cells, inducing 
transcription from quiescent HIV-1 LTRs. (II) Clearance. Once viral transcription has 
been induced, cells containing HIV-1 must be cleared. There are several 
mechanisms that may contribute to clearance. If HIV-1 transcription is sufficient to 
produce HIV-1 protein, HIV-1 antigens may be displayed on the cell surface, which 
may allow the immune system to target and destroy the infected cells. Alternatively, 
the cell may undergo apoptosis in response to HIV-1 production. Anti-retroviral 
therapy (ART) will be used to prevent de novo infection. Figure reproduced with 
permission from Barton, K. M., B. D. Burch, N. Soriano-Sarabia, and D. M. Margolis. 
2013. Prospects for Treatment of Latent HIV. Clinical Pharmacology and 
Therapeutics 93:46-56. 
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CHAPTER 2 
SELECTIVE TARGETING OF THE REPRESSIVE TRANSCRIPTION FACTORS 
YY1 AND cMYC TO DISRUPT QUIESCENT HUMAN IMMUNODEFICIENCY 
VIRUSES1
Overview 
Quiescent HIV-1 infection of resting CD4+ T cells is an obstacle to eradication 
of HIV-1 infection. These reservoirs are maintained, in part, by repressive complexes 
that bind to the HIV-1 long terminal repeat (LTR) and recruit histone deacetylases 
(HDACs). cMyc and YY1 are two transcription factors that are recruited as part of 
well-described, distinct complexes to the HIV-1 LTR and in turn recruit HDACs. In 
prior studies, depletion of single factors that recruit HDAC1 in various cell lines was 
sufficient to upregulate LTR activity. Short hairpin RNAs (shRNAs) were used to test 
the effect of targeted disruption of a single transcription factor on quiescent 
proviruses in T cell lines. In this study, it was found that depletion of YY1 significantly 
increases transcription of mRNA and protein expression from the HIV-1 promoter in 
some contexts, but does not affect HDAC1, HDAC2, HDAC3 or acetylated histone 3 
occupancy of the HIV-1 LTR. Conversely, depletion of cMyc or cMyc and YY1 does 
not significantly alter the level of transcription from the LTR or affect recruitment of 
HDACs to the HIV-1 LTR. Further, global inhibition of HDACs with the HDAC 
inhibitor suberoylanilide hydroxamic acid (SAHA) enhanced the increase in LTR 
transcription in cells that were depleted of YY1. These findings show that, despite 
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prior isolated findings, redundancy in repressors of HIV-1 LTR expression will 
require selective targeting of multiple restrictive mechanisms to comprehensively 
induce the escape of quiescent proviruses from latency.  
Introduction 
The transcription of quiescent proviral genomes is repressed by the presence 
of facultative heterochromatic structures, which contain high levels HDAC1, 
trimethylated lysine 9 of histone 3, trimethylated lysine 27 of histone 3, HP1-", and 
low levels of acetylated histone 3 (26). Additonally, the quiescent HIV-1 long terminal 
repeat (LTR) is occupied by the repressive NURD and the NCoR histone 
deacetylase (HDAC) complexes in Jurkat and monocyte-derived macrophage cell 
lines, respectively (9, 14). These HDAC complexes repress transcription by 
removing acetyl groups from histones, which results in a repressive chromatin 
structure at the HIV-1 LTR that is not permissive for transcription. HDAC inhibitors 
are consistently able to reactivate quiescent HIV-1 in cell line models and in patients’ 
cell (1-3, 15). However, HDACs regulate the expression of a broad range of cellular 
factors, and HDAC inhibitors affect the acetylation of lysines on many non-histone 
proteins. Therefore, the aim of this study was to determine whether factors that 
specifically recruit HDACs to the HIV-1 promoter could be directly targeted to 
reverse HIV-1 quiescence. To date, several transcription factors have been 
described that recruit HDAC1 to the HIV-1 LTR, including cMyc, YY1, CBF1, NF-!b 
and Sp1 (15, 16, 25, 28). Surprisingly, although each of these factors binds to the 
LTR at a distinct location and individually recruits HDACs, previous studies have 
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found that single depletion of any one of these factors is sufficient to disrupt 
quiescent HIV-1 proviruses and occupancy of HDAC1 at the HIV-1 promoter. 
Furthermore, these findings indicate that in the absence of one HDAC recruiting 
complex, HDAC occupancy cannot be maintained at a level sufficient to prevent 
reactivation of HIV-1 transcription.   
YY1 and cMyc are two transcription factors that are recruited to the HIV-1 
promoter and are involved in maintenance of transcriptional repression. YY1 can 
both activate and repress transcription depending on the promoter context (8). YY1 
is recruited to the HIV-1 LTR by the transcription factor LSF and represses 
transcription by recruiting HDAC1 in HeLa cells (11, 15). cMyc is a transcription 
factor that is most commonly known for its roles in regulating cellular proliferation 
and cell growth. Like YY1, it is able to act as both a transcriptional activator and 
repressor depending on the context of the promoter (12). The mbIII domain of cMyc 
is important for its ability to repress transcription and mediates the interaction 
between cMyc and HDAC3 (19). cMyc is repressive when recruited to the HIV-1 LTR 
by the transcription factor Sp1 (16). However, cMyc is required for Tat activated HIV-
1 transcription (7). Because of their well-characterized role in the maintenance of 
quiescent HIV, cMyc and YY1 are promising targets for therapies to disrupt the 
silencing of integrated HIV-1 proviruses. 
Many of the initial studies that were instrumental in elucidating the 
mechanisms of HIV-1 transcriptional repression have been performed in HeLa cell 
lines. HeLa cells are an epithelial cell line that were originally isolated from cervical 
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cancer tissue (21). In vivo, HIV-1 infects CD4+ T cells of the immune system. The 
cell environment and transcriptional profiles of epithelial and T cells are very 
different. Therefore, mechanisms that maintain transcriptionally quiescent proviral 
genomes in T cells are of paramount relevance. Jurkat cells are a cell line derived 
from T cells with biochemical features similar to resting CD4+ T cells. Several cell 
lines that are derived from Jurkat cells and contain quiescent, but inducible HIV-1 
proviruses have been created as models of HIV-1 latency, including 2D10 and J89 
cells (18, 20). Studies were performed in 2D10 and J89 cells because unique 
proviral insertion sites, and perhaps subtle differences in cellular gene programming, 
result in widely distinct sensitivity to viral induction strategies. These studies more 
accurately reflect the diversity of HIV-1 latency in vivo than those performed in a 
single clonal model.  
The goal of this study was to determine whether the selective targeting of 
transcription factors, such as cMyc and YY1, that recruit HDACs to the LTR and 
maintain transcriptional repression of HIV-1, could disrupt latency in T cell lines. 
Further, to determine whether these factors play a unique or general role in the 
individual recruitment of HDAC1, HDAC2 and HDAC3 to the HIV-1 LTR. The 
mechanisms that maintain proviral quiescence are high-value therapeutic targets for 
the development of anti-latency therapies. 
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Materials and Methods 
Cell culture 
J89 (a kind gift from Dr. David Levy at the University of Alabama at 
Birmingham) and 2D10 (a kind gift from Dr. Jonathan Karn at Case Western 
Reserve University) cells were maintained in RPMI supplemented with 10% FBS 
and 1% Pen/strep in a 37˚C incubator containing CO2. Cells were passaged every 
three to four days, and all experiments were performed on cells that had been 
passaged fewer than twelve times. For the experiments in which suberoylanilide 
hydroxamic acid (SAHA, Merck Research Laboratories, West Point Pennsylvania) or 
phorbol 12-myristate 13-acetate (PMA, Sigma-Aldrich, St Louis, MO), was used, 
500 nM of SAHA or 10 nM of PMA was added to the cell media 54 hours after 
transduction with short-hairpin RNAs (shRNAs) and 18 hours prior to collection for 
flow cytometry. 
Chromatin Immunoprecipitation (ChIP) assays 
 Ten million cells that had been transduced with shRNAs were collected, 
washed once with PBS, and then fixed with 1% formaldehyde for 10 min. The cell 
nuclei were isolated according to the manufacture’s instructions and sonicated for 24 
minutes in a bioruptor (Diagenode, Denville, NJ) with intervals that consisted of 30 
seconds of sonication and 15 seconds of rest. To bind the antibodies to the beads, 
protein A and protein G Dynal beads (Invitrogen, Grand Island, NY) were incubated 
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with 5-10 #g of antibody. The following antibodies were used for the ChIP 
experiments: HDAC1 ChIP grade (Abcam, Cambridge, MA), HDAC2 ChIP grade 
(Abcam, Cambridge, MA), HDAC3 ChIP grade (Abcam, Cambridge, MA), histone 3 
ChIP grade (Abcam, Cambridge, MA) and acetylated histone 3 (Millipore, Billerica, 
MA). Then, the sonicated product was added and incubated at 4˚C overnight. The 
next day, the beads were washed once for five minutes with each of the following 
buffers: ChIP dilution buffer, low salt ChIP buffer, high salt ChIP buffer, LiCl ChIP 
buffer, and TE buffer. The samples were then eluted from the beads and incubated 
at 68˚C for two hours to decrosslink the proteins from the DNA and to degrade the 
protein. The DNA was purified using the Qiagen PCR purification kit (Qiagen, 
Valencia, CA) according to the manufacturer’s instructions. The enrichment of the 
HIV-1 LTR in the ChIP samples was assessed using qPCR (quantitative PCR). 
Independent transductions were performed for each ChIP replicate. 
Quantitative PCR 
One microliter of the DNA from the ChIP assay was used in a final volume of 
20 #l containing 10 #l of SYBR green master mix (Applied Biosystems, Foster City, 
CA) and 0.5 #M each of the primers LTRrt8 (5’-
TAGCCAGAGAGCTCCCAGGCTCAGA-3’) and LTRrt9 (5’-
AGCCCTCAGATGCTACATATAA GCA-3’). The reaction was run on a 7900 
quantitative PCR machine (Applied Biosystems, Foster City, CA) with the following 
parameters: 50˚C for 2 min; 95.0˚C for 10 min; and 40 replicates of 95.0˚C for 15 sec 
and 60˚C for 1 min. A standard curve ranging from 50% to .0008% of the total ChIP 
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input was run for each condition, and the data is displayed as the percent input with 
the background from the IgG condition subtracted. Experiments with less DNA than 
the IgG control sample were assigned zero quantity. Data is shown as the mean ± 
the standard error of the mean (SEM) from at least three independent ChIP 
experiments. The student’s t-test was used to assess significance, and a p-value of 
less than 0.05 was considered significant. 
Quantification of gene expression 
 2D10 or J89 cells that had been transduced with shRNAs were collected 72 
hours after transduction, and RNA was extracted using the RNeasy mini kit (Qiagen, 
Valencia, CA). The RNA was treated with DNase, and then 380 ng of RNA was 
reverse transcribed using the SuperScript III First-Strand synthesis kit (Invitrogen, 
Grand Island, NY) according to the manufacturer’s instructions. The reverse 
transcription quantitative PCR assay (RT-qPCR) was used to determine gene 
expression. The following primers and probes were used to amplify the cDNA: Gag-
F: 5’ ACATCAAGCAGCCATGCAAAT, GAG-R: 5’ TCTGGCCTGGTGCAATAGG, 
GAG FAM PROBE: 5’ CTATCCCATTCTGCAGCTTCCTCATTGATG; EGFP-F: 5’ 
GGAGCGCACCATCTTCTTCA, EGFP-R: 5’ AGGGTGTCGCCCTCGAA, EGFP 
FAM Probe: CTACAAGACCCGCGCCGAGGTG; HDAC1-F: 5’ 
TGAGGACGAAGACGACCCT, HDAC1-R: 5’ CTCACAGGCAATTCGTTTGTC, and 
HDAC1 FAM probe: 5’ CAAGCGCATCTCGATCTGCTCCTC (23); HDAC2-F: 5’ 
CTTTCCTGGCACAGGAGACTT, HDAC2-R: 5’ 
CTCATTGGAAAATTGACAGCATAGT, and HDAC2 FAM probe: 5’ 
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AGGGATATTGGTGCTGGAAAAGGCAA; and HDAC3-F: 5’ 
GGTGGTTATACTGTCCGAAATGTT, HDAC3-R: 5’ 
GCTCCTCACTAATGGCCTCTTC, and HDAC3 FAM probe: 5’ 
AGCAGCGATGTCTCATATGTCCAGCA. Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) was amplified for each sample and used for normalization. 
The primers and probes used were as follows: GAPDH-F: 5’ 
GCACCACCAACTGCTTAGCACC, GAPDH-R: 5’ TCTTCTGGGTGGCAGTGATG, 
and GAPDH HEX probe: 5’ TCGTGGGAAGGACTCATGACCACAGTCC (27). 
Results are displayed as the fold increase over the control condition, which was 
calculated using the !!ct method. The values shown represent the mean of three 
independent experiments ± the SEM. 
Western Blots 
 J89 or 2D10 cells were collected 72 hours after being transduced with 
lentiviruses carrying shRNAs. Protein was extracted with radioimmunoprecipitation 
assay buffer containing 10 #l Protease Inhibitor Cocktail (Sigma-Aldrich, St Louis, 
MO) and 10 mM NaF (Sigma-Aldrich, St Louis, MO). The quantity of protein was 
determined using a Bradford protein assay according to the manufacture’s 
instructions (Bio-Rad, Hercules, CA). Five to ten micrograms of protein was loaded 
onto a 4%-12% bis-tris gel (Invitrogen, Grand Island, NY). The western blot was then 
run as previously described (17). The following primary antibodies were used: 
HDAC1, HDAC2, HDAC3, cMyc, and YY1 (all from Santa Cruz Biotechnology, Santa 
Cruz, CA) and alpha tubulin (Abcam, Cambridge, MA) was used as a loading 
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control. The band intensity of the Western blots was analyzed using Image J 
software (NIH, Bethesda, MD).  Each Western blot was performed using cells from 
independent transductions at least three times. The values shown represent the 
mean percent protein knockdown ± the SEM from three independent experiments. 
Transduction of shRNAs  
Three million cells were split into 12 mL of RMPI media containing 10% FBS 
and 1% pen/strep and incubated overnight. At 24 hours the cells were transduced 
with lentiviral vectors carrying cMyc or YY1 shRNAs, and the cells were incubated at 
37˚C overnight. shRNA plasmids and lentiviruses were obtained from the UNC Lenti-
shRNA core facility, which has the Open Biosystems shRNA library (Open 
Biosystems, Lafayette, CO). The plasmid TRCN0000039642 was used to deplete 
cMyc, and plasmid TRCN0000019898 was used to deplete YY1. A plasmid 
containing a shRNA to eGFP was used as the non-specific (NS) control in the ChIP 
experiments (catalog number RHS4459, Open Biosystems Lafayette, CO). The 
pLKO.1 empty vector control (catalog number RHS4080, Open Biosystems, 
Lafayette, CO) was used as the negative control for the RT-qPCR and flow 
cytometry experiments. Twenty-four hours after the addition of the shRNA, new 
media and 2 #g/mL of puromycin was added to select for cells that had been 
transduced. The cells were then incubated at 37˚C for 48 hours before collection for 
downstream applications. New transductions were performed for each experiment, 
and cells were never frozen down and thawed for subsequent experiments. 
Knockdown was assessed by qPCR and Western blot as described above. 
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Flow cytometry 
Cells were collected 72 hours after transduction with lentiviruses, washed 
once with 1X PBS, and then fixed in 3.2% paraformaldehyde. The GFP expression 
of the cells in the fixed samples was measured using an Attune flow cytometer 
(Applied Biosystems, Foster City, CA) or a CyAn ADP analyzer (Beckman Coulter, 
Inc., Brea, CA, UNC flow cytometry core facility). At least 10,000 cells were collected 
for each condition. The analysis was performed using FlowJo flow cytometry 
analysis software (FlowJo, Ashland, OR). The values shown are the mean of three 
independent experiments ± the SEM from at least three independent experiments. 
Results 
Depletion of cMyc and YY1 in Jurkat cells does not affect cell viability 
To determine whether cMyc and YY1 are required to maintain transcriptional 
repression of the HIV-1 provirus in Jurkat cells, the RNA interference pathway was 
used to deplete the mRNA transcripts of cMyc and YY1, and the downstream effects 
were monitored.  
In this study, shRNAs were used instead of siRNAs for three important 
reasons. First, Jurkat cells are very difficult to transfect, which is the primary method 
that is used to introduce siRNAs into cells and the transfection procedure can cause 
sufficient cell stress to activate expression from the HIV promoter, which makes it 
difficult to interpret the results from these types of experiments. Jurkat cells can be 
transduced with lentiviruses carrying shRNA expressing vectors relatively efficiently. 
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Secondly, siRNAs are rapidly used up, which results in a short duration of mRNA 
depletion that may not correspond to a significant protein depletion depending on the 
half-life of the protein. shRNAs are continually expressed from a lentiviral vector 
resulting in a sustained depletion. Thirdly, the shRNA vector contains a puromycin 
resistance gene that allows for selection of cells carrying the shRNA containing 
vector.  
Specifically, transduction was used to deplete the transcription factors cMyc 
and YY1. Transduction of cMyc specific shRNAs reduced the amount of cMyc in 
2D10 cells by 85% and in J89 cells by 72% (Fig. 2.1 and data not shown). Single 
depletion of YY1 with shRNAs reduced the amount of YY1 protein by 87% in 2D10 
cells and 56% in J89 cells (Fig. 2.1 and data not shown). Furthermore, the 
transduction of both cMyc and YY1 shRNAs reduced protein levels by 57% and 83% 
in 2D10 cells and by 86% and 62% in J89 cells, respectively (Fig. 2.1 and data not 
shown). The transduced cells were then selected with puromycin to ensure that the 
study population of cells homogenously carried the shRNA-expressing vector. The 
CellTiter-Blue cell viability assay (Promega, Madison, WI) was used to determine the 
effect of YY1, cMyc or YY1 and cMyc depletion on the viability of Jurkat cells. 
Transducing Jurkat cells with cMyc, YY1 or cMyc and YY1 shRNAs does not 
significantly affect the viability of 2D10 or J89 cells as compared to the cells that 
were transduced with the vector control plasmid (Fig. 2.1d and data not shown). 
Therefore, lentivirus transduction of shRNAs is an effective technique for the 
depletion of cMyc and YY1 in Jurkat cells and does not significantly affect cell 
viability.  
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Knockdown of the transcription factors cMyc, YY1 or both does not affect 
protein or mRNA expression of HDAC1, HDAC2 or HDAC3 
cMyc and YY1 both affect the expression and post-transcriptional regulation 
of a significant number of cellular genes (8, 12). Because cMyc and YY1 are both 
broadly acting transcription factors, it is possible that they could affect HIV-1 
transcription by regulating the expression of HDACs. Furthermore, cMyc has 
recently been shown to regulate the transcription of HDAC2 in mesenchymal stem 
cells (6). Therefore, to ensure that the effects of depleting cMyc and YY1 were not 
related to an effect on HDAC expression, the levels of the HDAC proteins were 
measured using Western blot and mRNA using RT-qPCR after depletion of cMyc, 
YY1 or cMyc and YY1 (Fig. 2.2). No significant changes in the protein levels of 
HDAC1, HDAC2 or HDAC3 were observed by Western blot after knockdown of 
cMyc, YY1, or cMyc and YY1 in 2D10 or in J89 cells (Fig. 2.2a and data not shown). 
Furthermore, depletion of cMyc, YY1 or cMyc and YY1 did not significantly affect 
HDAC1, HDAC2 or HDAC3 mRNA expression when compared to the cells 
transduced with the vector control (Fig. 2.2). Therefore, the effects of depleting 
cMyc, YY1 or cMyc and YY1 with shRNAs is not mediated by a secondary depletion 
of HDAC1, HDAC2 or HDAC3 in 2D10 or J89 cells (Fig. 2.2 and data not shown).  
Individual depletion of the transcription factor YY1 significantly increases 
expression from the HIV-1 LTR. 
Targeting cMyc or YY1 containing complexes upregulates expression of HIV-
1 mRNA in HeLa cell line models of HIV-1 latency (11, 16, 24). To determine 
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whether these transcription factors are also important for maintaining HIV-1 
transcriptional repression in a T cell line, cMyc, YY1 or cMyc and YY1 were depleted 
from J89 or 2D10 Jurkat T cells, and expression from the HIV-1 LTR was monitored 
using RT-qPCR and flow cytometry. The proviral genomes in both J89 and 2D10 
cells contain GFP, which can be used to monitor expression from the HIV-1 LTR. In 
J89 cells, the GFP gene is inserted between the env and nef genes of the HIV-1 
provirus (20). In 2D10 cells, the GFP gene is inserted between env and the 3’LTR 
and nef is deleted (18). Additionally, 2D10 cells contain an attenuated tat and a 
truncated gag (18). Because the provirus in the 2D10 cells does not contain the 
complete gag sequence, RT-qPCR was used to monitor GFP mRNA expression in 
the 2D10 cells as a measure of HIV-1 LTR activity. Following depletion of YY1 from 
the 2D10 cells there was a significant 4.2 fold increase in GFP mRNA expression 
from the HIV-1 LTR (Fig. 2.3a, p-value < 0.05 ). However, GFP mRNA expression 
did not increase significantly following depletion of cMyc in the 2D10 cells (Fig. 
2.3a). Furthermore, depletion of cMyc or YY1 did not result in a significant increase 
in expression of gag mRNA in the J89 cells (Fig. 2.3c). 
To further determine whether the effects seen at the mRNA level were 
reflected at the protein level, the percentage of cells expressing GFP was measured 
using flow cytometry. The percentage of 2D10 cells expressing GFP that were 
depleted of YY1 significantly increased over six fold when compared to the cells 
transduced with the vector control, which correlates with the observed increase in 
GFP mRNA that was observed (Fig. 2.3b, p-value < 0.05). Following knockdown of 
cMyc there was not a significant increase in the percentage of 2D10 or J89 cells 
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expressing GFP (Fig. 2.3b and 3d). Additionally, no increase in the percentage of 
J89 cells expressing GFP was observed following YY1 depletion (Fig. 2.3d).  
Because cMyc and YY1 can both act as transcriptional activators as well as 
repressors, next it was important to determined whether cMyc or YY1 were required 
for HIV-1 transcription by adding PMA to 2D10 or J89 cells that were depleted of 
YY1, cMyc or both for 24 hours and measuring the percentage of GFP positive cells 
by flow cytometry. PMA induced a significant percentage of cells to express HIV-1 
driven GFP over the cells that were treated with DMSO in the cells depleted of cMyc, 
YY1 or cMyc and YY1. Furthermore, there was no significant difference in the 
percentage of GFP positive cells after exposure to PMA in the cells depleted of 
cMyc, YY1 or cMyc and YY1 as compared to the cells transduced with the control 
shRNA, which indicates that cMyc nor YY1 is required to induce transcription from 
the HIV-1 LTR (Fig 2.8). 
Together, these results suggest that YY1 is involved in repression of the HIV-
1 LTR, but that its effects predominate in select cellular contexts. The different 
response of the two cell lines to YY1 depletion may be due to differences between 
the locations of the proviral genomes in these two cell lines or the degree of 
repressive chromatin structures that have developed at the LTR. These results also 
indicate that depletion of cMyc or cMyc and YY1 is not sufficient to induce 
expression from the HIV-1 LTR in these Jurkat cell lines. Furthermore, neither cMyc 
nor YY1 is required for expression from the HIV-1 LTR. Of relevance to the 
development of translational strategies to deplete persistent HIV-1 infection, these 
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findings demonstrate some redundancy or overlap in epigenetic mechanisms that 
maintain proviral latency. 
Depletion of cMyc or YY1 does not significantly affect HDAC occupancy of the 
HIV-1 LTR. 
Of the 11 human HDACs, only HDAC1, HDAC2, and HDAC3 have been 
shown to play a critical, direct role in the regulation of HIV-1 LTR expression (17). In 
HeLa cell lines containing quiescent proviral genomes, depletion of cMyc or YY1 
leads to transcription from the HIV-1 LTR through depletion of HDAC1 occupancy 
(11, 16). cMyc and YY1 are both associated with recruitment of HDACs and HDAC 
complexes to LTR of HIV-1 and to the promoters of some cellular genes (19). 
Furthermore, HDAC inhibitors are consistently able to activate HIV-1 transcription in 
both cell line models and in patients’ cells (2, 3, 10). Therefore, the next step of this 
study was to determine whether depleting factors that recruit HDACs to the HIV-1 
promoter, cMyc and YY1, had an effect on the recruitment of HDACs to the HIV-1 
LTR. Following depletion of cMyc or YY1, chromatin immunoprecipitation (ChIP) was 
used to measure the occupancy of HDAC1, HDAC2, and HDAC3 in 2D10 and J89 
Jurkat cells (Fig. 2.4). Depletion of cMyc or YY1 from 2D10 and J89 cells did not 
significantly alter HDAC1, HDAC2 or HDAC3 occupancy of the HIV-1 LTR (Fig. 2.4). 
Although cMyc and YY1 are known to interact with HDACs and HDAC complexes, 
this result indicates that depletion of these factors is not sufficient to measurably 
block HDAC recruitment to the HIV-1 LTR in these Jurkat cell lines. This finding is 
consistent with earlier results that found that depletion of cMyc or cMyc and YY1 did 
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not significantly affect HIV-1 expression from these cell lines. However, the lack of 
change in HDAC occupancy of the HIV-1 LTR following depletion of YY1 suggests 
that the induction of HIV-1 transcription after YY1 knockdown is induced by an effect 
that does not affect HDAC occupancy at the HIV-1 promoter. 
Acetylation of histone 3 increases at the promoters of activated genes, and 
given sufficient gene expression and chromatin remodeling, H3 histone occupancy 
may decrease (13, 22). Therefore, to further examine the landscape of the HIV-1 
LTR following depletion of cMyc, YY1 or cMyc and YY1 the occupancy of histone 3 
and acetylated histone 3 was assessed (22). A significant increase in histone 
acetylation was observed following depletion of cMyc in 2D10 cells (Fig. 2.5b, p-
value < 0.05). This upregulation in histone acetylation was not accompanied by a 
significant increase in HIV-1 expression or a significant change in HDAC occupancy 
of the HIV-1 LTR. No significant changes in histone acetylation were observed in 
J89 cells following cMyc depletion or in either cell line following YY1 depletion (Fig. 
2.5). The lack of change in histone 3 acetylation at the HIV-1 LTR following YY1 
depletion is surprising given the increase in mRNA expression that was observed 
and indicates that depletion of YY1 alone is sufficient to disrupt repression of the 
HIV-1 LTR even in the presence of HDACs. The lack of change in HDAC occupancy 
following selective disruption of the YY1/LSF complex or the cMyc/Sp1 complex 
indicates that other factors are present at the HIV-1 LTR that are able to recruit 
HDACs in the absence of these complexes (11, 16). 
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Depletion of cMyc and YY1 does not affect quiescent HIV-1 expression in 
Jurkat cells 
Given the possibility that LTR quiescence is maintained by redundant 
systems capable of recruiting HDACs to the HIV-1 LTR, both cMyc and YY1 were 
depleted from J89 and 2D10 cells. However, after knockdown of both cMyc and 
YY1, there was not a significant increase in HIV-1 mRNA expression in J89 or 2D10 
cells (Fig. 2.3a and 2.3b). Correspondingly, there was not a significant change in the 
percentage of cells expressing GFP following depletion of both factors from either 
cell line (Fig. 2.3c and 2.3d). Therefore, depletion of these two HDAC recruiting 
factors in not sufficient to disrupt the maintenance of quiescent HIV. 
Furthermore, after depletion of both cMyc and YY1 there was not a significant 
change in the occupancy of HDAC1, HDAC2 or HDAC3 at the HIV-1 LTR as 
measured by ChIP assay (Fig. 2.6). This suggests that derepression of the HIV-1 
LTR in T cell lines, unlike in HeLa cells, may require targeting of additional or 
different transcription factors. Furthermore, there were no significant changes in 
histone 3 occupancy or acetylation at the HIV-1 LTR in either 2D10 or J89 cells 
following depletion of cMyc and YY1 (Fig. 2.6). Altogether, this data indicates that a 
complex network of factors are involved in the maintenance of HIV-1 quiescence in 
Jurkat cells and that in the absence of cMyc and YY1, other mechanisms maintain 
recruitment of HDACs to the HIV-1 LTR.  
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The effect of YY1 depletion is enhanced by HDAC inhibition. 
The modest effects of cMyc and YY1 depletion on HDAC recruitment to the 
HIV-1 LTR were surprising because both have previously been shown to repress 
transcription of the HIV-1 LTR through HDAC recruitment. However, as ChIP assays 
are only semi-quantitative, an alteration of HDAC occupancy that is functionally 
important might not be detected. Therefore, because RNAi depletion did not achieve 
complete inhibition of protein expression and to further determine whether cMyc and 
YY1 were involved in repression of the HIV-1 promoter, 2D10 and J89 cells were 
treated with the HDAC inhibitor SAHA and the effects of depleting cMyc, YY1 or 
cMyc and YY1 from 2D10 and J89 cells was assayed. Eighteen hours after the 
addition of a maximal concentration of SAHA (500 nM) to cells that had been 
transduced with the vector control, approximately 9.23% of the 2D10 cells were 
found to be expressing GFP. However, the addition of SAHA in combination with 
depletion of YY1 significantly increased the effect of YY1 knockdown and induced 
GFP expression in approximately 32% of the 2D10 cells (Fig. 2.7, p-value < 0.05). 
Because the concentration of SAHA used is able to completely inhibit HDACs, the 
significant increase in expression when SAHA is added to YY1 depleted cells 
indicates that YY1 mediates repression of HIV-1 transcription through a non-HDAC 
mechanism.  
Inhibition of HDACs with 500 nM of SAHA did not augment the effects of 
depleting cMyc or cMyc and YY1 in 2D10 cells (Fig. 2.7). Furthermore, no significant 
changes in LTR expression were observed in J89 cells that were treated with SAHA 
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in combination with depletion of cMyc, YY1 or cMyc and YY1 (data not shown). This 
finding indicates that there are indeed multiple mechanisms involved in the 
repression of HIV-1 transcription and that targeting multiple factors can result in 
increased HIV-1 expression. 
Discussion 
 cMyc and YY1 bind to the HIV-1 LTR and regulate transcription through 
recruitment of HDACs (11, 16). To determine whether selective anti-latency therapy 
could be specifically targeted to transcription factors that recruit HDACs to the HIV-1 
LTR. Depletion of cMyc, YY1 or cMyc and YY1 did not significantly affect 
transcription or protein levels of the HDAC proteins, which indicates that the effects 
on HIV-1 transcription are not a secondary effect of changes in HDAC expression. 
Depletion of YY1 resulted in a significant four-fold increase in mRNA expression and 
a significant increase from approximately .7% of the cells in the control shRNA 
condition to 4.2% of the cells depleted of YY1 expressing the GFP protein from the 
HIV-1 LTR in the 2D10 cells but not in J89 cells (Fig. 2.3). However, in contrast to 
studies in HeLa cells, single knockdown of cMyc did not have a significant effect on 
transcription of mRNA from the HIV-1 LTR or on the induction of GFP protein 
expression from the HIV-1 LTR (Fig. 2.3). Furthermore, depletion of cMyc and YY1 
together did not induce HIV-1 transcription in either cell line. As cMyc has been 
show to be required for Tat mediated elongation of the HIV-1 promoter (7), it is 
possible that cMyc’s role in elongation may account for the lack of HIV-1 
transcription that was observed after depletion of YY1 and cMyc and may explain 
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why the significant increase in histone 3 acetylation did not correlate with an 
increase in expression. Depletion of cMyc, YY1 or cMyc and YY1, followed by 
activation with PMA, induced a significant amount of expression from the HIV-1 LTR 
in 2D10 and J89 cells (Fig. 2.8). Therefore, it can be concluded that cMyc is not 
absolutely required for activation of the HIV-1 promoter by PMA. However, because 
depletion of cMyc and YY1 resulted in less activation of the HIV-1 promoter than 
depletion of YY1 alone, the mechanism of repression that is mediated by YY1 may 
act through a pathway that requires cMyc. These results are particularly surprising in 
light of previous studies that found disruption of cMyc or YY1 was sufficient to 
disrupt quiescent HIV-1 proviruses. Because YY1 depletion did not activate HIV-1 
transcription in both cell lines, targeting YY1 as part of a future anti-latency therapy 
may not broadly disrupt latency in all proviral integrants. 
When markers of repressive and activated promoters were further studied at 
the HIV promoter using ChIP following knockdown of cMyc, YY1 or cMyc and YY1, 
no significant change in histone 3 occupancy of the HIV-1 LTR was observed.  The 
lack of change in histone 3 occupancy indicates that nucleosomes at the HIV-1 
promoter were not significantly disrupted following depletion of cMyc, YY1 or both 
factors. Although cMyc and YY1 are known to recruit HDACs to the HIV-1 LTR in 
HeLa cells, the ChIP results from this study indicate that they are not absolutely 
required to recruit HDAC1, HDAC2 or HDAC3 to the HIV-1 LTR in Jurkat cells. 
Contrary to previous findings, these results indicate that in T cells, other transcription 
factors that bind to the HIV-1 LTR may be able to compensate for the loss of cMyc, 
YY1 or both and maintain HDAC occupancy. Specifically, NF-!b and CBF1 have 
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been implicated in recruitment of HDAC1 to the HIV-1 LTR may be able to 
compensate for the loss cMyc and YY1 (25, 28). Furthermore, these or other 
proteins may contribute to the repression of HIV-1 transcription in T cells. 
Additionally, these finding highlight an important difference between HeLa cell line 
models of HIV-1 latency and T cell line models of HIV-1 latency and indicate that the 
epigenetic environment surrounding the HIV-1 LTR in HeLa cells may be less stable 
than in T cells. In light of the results in this study, the benefits and limitations of the 
HeLa cell model should be carefully considered before future studies are performed 
using HeLa cells to study HIV. Although Jurkat cells more closely resemble primary 
CD4+ T cells, it is still important to develop more advanced tools and model system 
for the future study of the epigenetics of quiescent HIV-1 proviruses.  
Interestingly, targeting HDAC recruitment through depletion of YY1 in 
conjunction with HDAC inhibition resulted in a significant increase in GFP protein 
expression from the HIV-1 promoter. This finding indicates that targeting multiple 
restrictive mechanisms at the HIV-1 LTR may be an innovative method for disrupting 
HIV-1 latency. YY1 is involved in several malignancies and some new classes of 
chemotherapeutics have been demonstrated to decrease expression of YY1 (5). 
Such approaches might be used for the treatment of latent HIV-1 infection, and may 
be able to augment the effects of SAHA (4). However, additional development of 
drugs that directly target the protein interaction domains of YY1 could be pursued 
and could possibly be used in conjunction with compounds that are currently being 
studied to perturb quiescent HIV such as SAHA. 
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Previous studies have found that the chromatin environment surrounding the 
HIV-1 insertion site may affect transcription. Furthermore, in vivo infected CD4+ T 
cells have a range of insertion sites. To account for the effect of insertion site 
differences, the studies were performed in two Jurkat cells lines with distinct proviral 
insertion sites. The differences seen between the two cells lines may be attributable 
to the difference in proviral locations. However, apart from the effects of YY1 
depletion, most of the results were seen in both cell lines, indicating that the proviral 
location may have had only modest effects. The differences in results found in this 
study as compared to previous studies in HeLa cells highlights the importance of 
conducting studies in multiple lineages of cell lines. Although Jurkat cells are derived 
from CD4+ T cells, there are still some important differences between these cells 
and in vivo HIV-1 infected cells. Therefore, our lab and others are working to 
develop models of HIV-1 quiescence that more accurately mimic the in vivo 
environment of HIV-1 quiescence. 
In conclusion, the results indicate that depletion of the transcription factor YY1 
using transduction of shRNAs in Jurkat cells is sufficient to disrupt the repression of 
the HIV-1 promoter in select cellular contexts. However, depletion of the 
transcription factor cMyc does not induce HIV-1 expression in Jurkat cells. 
Importantly, depletion of cMyc, YY1 or cMyc and YY1 is not sufficient to disrupt the 
binding of HDAC complexes to the HIV-1 LTR in Jurkat cells. Therefore, it can be 
concluded that the mechanism of maintenance of HIV-1 transcriptional repression is 
complex and may require a combination of therapies that target multiple levels or 
several factors to reverse transcriptional repression of the HIV-1 LTR.  
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Figure 2.1. Depletion of cMyc or YY1 does not affect Jurkat cell viability. 
Lentiviral shRNAs specific to cMyc, YY1 or cMyc and YY1 significantly deplete the 
protein levels of cMyc (a), YY1 (b) or cMyc and YY1 (c) in 2D10 cells as determined 
by Western blot analysis. d) Depletion of cMyc, YY1 or cMyc and YY1 does not 
affect the viability of 2D10 cells 72 h after transduction of shRNAs. 
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Figure 2.2. Depletion of cMyc, YY1 or cMyc and YY1 does not significantly 
affect expression of HDAC1, HDAC2 or HDAC3 in 2D10 cells. a) HDAC1, 
HDAC2 and HDAC3 protein levels remain stable in 2D10 cells after depletion of 
cMyc, YY1 or cMyc and YY1. (b) HDAC1, (c) HDAC2, or (d) HDAC3 mRNA 
expression levels are not significantly affected by the depletion of cMyc, YY1 or 
cMyc and YY1 in 2D10 cells as measured by RT-qPCR. 
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Figure 2.3. Depletion of YY1 significantly increases HIV-1 expression in 2D10 
cells a) GFP mRNA expression from the HIV-1 LTR significantly increased after 
depletion of YY1 from 2D10 cells. No changes were observed in GFP mRNA 
expression levels following depletion of cMyc or cMyc and YY1 from 2D10 cells. b) 
The percentage of 2D10 cells expressing GFP protein, as determined by flow 
cytometry, significantly increased after depletion of YY1, but not after depletion of 
cMyc or cMyc and YY1. c) Expression of gag mRNA was not significantly affected by 
knockdown of cMyc, YY1 or both in J89 cells. d) The percentage of J89 cells 
expressing GFP protein, as determined using flow cytometry, did not significantly 
increase after knockdown of cMyc, YY1 or cMyc and YY1. * indicates a p-value of 
less than 0.05. 
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Figure 2.4. HDAC occupancy of the HIV-1 promoter is not affected by depletion 
of cMyc or YY1. a) HDAC1, b) HDAC2 and c) HDAC3 occupancy of the HIV-1 
promoter was not significantly altered after depletion of cMyc or YY1 from 2D10 
cells, as determined using a ChIP assay. d) HDAC1, e) HDAC2 and f) HDAC3 
occupancy of HIV-1 LTR did not change significantly after depletion of cMyc or YY1 
from J89 cells as measured by ChIP assay. 
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Figure 2.5. Histone 3 and acetylated histone 3 levels on the HIV-1 promoter did 
not significantly change following depletion of cMyc or YY1 in Jurkat cells. a 
and c) Histone 3 occupancy of the HIV-1 promoter in 2D10 (a) and J89 (c) cells did 
not significantly change following depletion of cMyc or YY1. b) The levels of histone 
3 acetylation significantly increased after depletion of cMyc in 2D10 cells. However, 
the level of acetylated histone 3 did not change following knockdown of cMyc or YY1 
in J89 cells (d) or after depletion of YY1 in 2D10 cells (b). * indicates a p of less than 
0.05. 
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Figure 2.6. Concurrent knockdown of cMyc and YY1 did not significantly affect 
HDAC1, 2, or 3 recruitment to the HIV-1 promoter or the levels of histone 3. 
Depletion of cMyc and YY1 from 2D10 cells did not affect the levels of HDAC1 (a), 
HDAC2 (b), HDAC3 (c), histone 3 (d) or acetylated histone 3 (e) at the HIV-1 LTR. 
Similarly, no changes in HDAC occupancy or histone 3 occupancy or acetylation 
was observed at the HIV-1 LTR following depletion of cMyc and YY1 in J89 cells (f-j) 
as measured by ChIP. 
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Figure 2.7. Targeting YY1 and HDAC activity significantly increases 
expression from the HIV-1 LTR. Depletion of YY1 in conjunction with the addition 
of 500 nM of SAHA for 18 h resulted in a significant increase in the percentage of 
2D10 cells expressing GFP as compared to cells that were transduced with the 
vector control and treated with SAHA as measured using flow cytometry. Depletion 
of cMyc or cMyc and YY1 in combination with SAHA did not significantly increase 
the percentage of 2D10 cells expressing GFP. * indicates a p-value of less than 
0.05. 
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Figure 2.8. Expression from the HIV-1 LTR does not require cMyc or YY1. 
Depletion of cMyc, YY1 or cMyc and YY1 followed by incubation with 10 nM PMA for 
18 h resulted in a significant increase in expression from the HIV-1 LTR in 2D10 and 
J89 cells over treatment with DMSO only. However, no significant changes were 
observed in the amount of expression from the HIV-1 LTR between 2D10 or J89 
cells that were depleted of cMyc, YY1 or cMyc and YY1 as compare to the cells 
transduced with the vector control following treatment with PMA. 
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therapeutic target for HIV latency (2013). (In revision) 
CHAPTER 3 
HDAC3 IS A KEY THERAPEUTIC TARGET FOR THE DISRUPTION OF LATENT 
HIV-1 INFECTION1 
 
Overview 
Selective histone deacetylase (HDAC) inhibitors have emerged as a potential 
anti-latency therapy for persistent human immunodeficiency virus type 1 (HIV-1) 
infection. A short hairpin (sh)RNA-mediated knockdown strategy was used to 
delineate the key HDAC(s) to be targeted by inhibitors for optimal induction of latent 
HIV-1 expression. Individual depletion of HDAC3 significantly induced expression 
from the HIV-1 promoter in the 2D10 latency cell line model. However, depletion of 
HDAC1 or -2 alone or in combination did not significantly activate HIV-1 induced 
expression. Co-depletion of HDAC2 and -3 resulted in a significant increase in 
expression from the HIV-1 promoter. Furthermore, concurrent knockdown of 
HDAC1, -2, and -3 resulted in a significant increase in expression from the HIV-1 
promoter. When the residual HDAC activity was inhibited after depletion of HDAC1, -
2 or -3 with small molecules the effect of depletion of HDAC3 alone was further 
enhanced. Thus, HDAC3 is essential for suppression of HIV-1 transcription and may 
be an important target for future therapeutics that seek to purge and eradicate latent 
HIV-1 infection. 
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Introduction 
 During latency, several restrictive factors are associated with the HIV-1 long 
terminal repeat (LTR) promoter that block efficient transcriptional initiation and 
mRNA elongation. Among these factors are HDACs, which are a family of enzymes 
that regulate transcription of numerous cellular and viral genes by removing acetyl 
groups from the lysine residues on both histones and non-histone proteins (6, 20). 
Deacetylation of histone tails results in removal of important docking signals that are 
required for binding of activating transcription factors. The result is an overall 
repressive transcriptional environment. HDACs are divided into four classes based 
upon their amino acid sequence and domain organization (10). The class I HDACs 
include HDAC1, -2, -3, and -8. HDAC4, -5, -6, -7, -9, and -10 make up the class II 
HDACs, and HDAC11 is the sole member of class IV. Class III HDACs include 
sirtuins 1-7, which are nicotinamide adenine dinucleotide-dependent deacetylases 
that are structurally unrelated to class I, II, and IV HDACs. Class III HDACs are not 
sensitive to the type of HDAC inhibitors that induce HIV-1 expression. 
Nonselective and class I-selective HDAC inhibitors are potent inducers of 
HIV-1 expression in both cell line models and ex vivo outgrowth assays using resting 
CD4+ T cells from HIV-1-infected individuals (3, 9, 24, 25, 30). Furthermore, the 
HDACi SAHA activates expression from quiescent proviruses in vivo (2). The class I 
HDACs, HDAC1, -2, and -3, are recruited to the HIV-1 LTR in cell line models of 
HIV-1 latency (4, 16, 20, 26, 28). These class I HDACs are highly expressed in the 
nuclei of resting CD4+ T cells and inhibitors selective for HDAC1, -2, and -3 are 
strong inducers of latent HIV-1 expression in resting CD4+ T cells (4). However, 
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inhibitors selective for the class II HDACs do not induce expression of HIV-1 (4). 
HDAC4, -6, or -7 have not been demonstrated to directly bind to the HIV-1 LTR (4). 
Highly selective inhibitors for HDAC1, -2, or -3 in isolation are not yet available, and 
an inhibitor selective for HDAC1 and HDAC2—but not HDAC3—does not activate 
latent HIV-1 (4). This data suggests that HDAC3 enzymatic inhibition is crucial for 
induction of expression from quiescent HIV-1 proviruses, but it is unclear if 
simultaneous inhibition of HDAC1 and -2 is also needed. Determining the minimum 
HDAC inhibition required to induce latent HIV-1 expression may focus efforts to 
identify and develop selective HDAC inhibitors for anti-latency therapies that would 
have fewer effects on cellular promoters and gene expression when compared to 
pan-HDAC inhibition. 
In an effort to better understand the role of individual class I HDACs in 
regulation of HIV-1 transcription, the impact of isolated and combination shRNA-
mediated depletion of HDAC1, -2, and -3 on HIV-1 expression in a T cell line model 
of latency was explored.  
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Materials and methods 
2D10 cells  
2D10 cells were cultured in RPMI 1640 with 10% FBS, 100 U/ml penicillin 
(Invitrogen), and 100 #g/ml streptomycin (Invitrogen). All experiments were 
performed using cells that had been passaged fewer than ten times. Cell cultures 
were maintained at 37°C under 5% CO2. 
Flow cytometry analysis  
First, the cells were washed once in PBS and then fixed in PBS containing 
3.2% paraformaldehyde. Flow cytometry was performed using an Attune flow 
cytometer (Applied Biosystems, Carlsbad, CA). Analysis of GFP expression was 
performed using FlowJo software (Tree Star in.; Ashland, OR) and the statistical 
analysis was performed using GraphPad Prism software (La Jolla, CA). Results are 
shown as the mean of at least three independent experiments, and the error bars 
indicate the standard error of the mean. 
Transduction of shRNAs  
Three million 2D10 cells were aliquoted into fresh media 24 h prior to 
transduction. Then, lentiviruses containing shRNAs specific to the individual HDACs 
were added to the 2D10 cells, and 2 #g/ml puromycin was added to the cells 24 h 
after addition of lentiviruses to select for cells containing the shRNA expressing 
vectors. In experiments that required drugs to be added to the cells, the drugs were 
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added at 72 h post-transduction. At 96 h post-transduction, cell samples were 
collected for flow cytometry and mRNA expression analysis. Independent 
transductions were performed for each experiment. Values shown are the mean of 
at least three independent experiments, and the error bars indicate the standard 
error of the mean (SEM). 
HDAC inhibitors 
2D10 cells that had been depleted of HDAC1, -2, or -3 with shRNAs were 
incubated with the indicated HDAC inhibitors for 18 h. Merck 12 was used at a 
concentration of 20 #M, Merck 13 was used at a concentration of 200 nM, and 
SAHA was used at a concentration of 250 or 500 nM. Mrk12, Mrk13, and SAHA 
were generously provided by Merck Research laboratories (West Point, PA). TSA 
(T8552, Sigma, St Louis, MO) was used at a concentration of 25 nM and droxinostat 
(S1422, Selleckchem.com, Houston, TX) was used at a concentration of 2 #M.  
RNA extraction and quantitative RT-PCR  
RNA was extracted from cells using a QIAgen RNeasy Mini Kit (Valencia, CA) 
following the manufacturer’s protocol. DNA was removed from RNA extracts by 
DNAse digestion (Promega; Madison, WI), and cDNA was synthesized using the 
SuperScript III First-Strand Synthesis for RT-PCR kit from Invitrogen. Quantitative 
PCR was performed on cDNA with a Bio-Rad CFX96 or CFX384 using QuantiTect 
Multiplex PCR Mastermix (QIAgen) and the following primer pairs and 5’ FAM-
labeled probes: HDAC1 5’ TGAGGACGAAGACGACCCT (forward), 5’ 
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CTCACAGGCAATTCGTTTGTC (reverse), and 5’ 
CAAGCGCATCTCGATCTGCTCCTC (probe) (23); HDAC2 5’ 
CTTTCCTGGCACAGGAGACTT (forward), 5’ 
CTCATTGGAAAATTGACAGCATAGT (reverse), and 5’ 
AGGGATATTGGTGCTGGAAAAGGCAA (probe); and HDAC3 5’ 
GGTGGTTATACTGTCCGAAATGTT (forward), 5’ GCTCCTCACTAATGGCCTCTTC 
(reverse), and 5’ AGCAGCGATGTCTCATATGTCCAGCA (probe). Expression of 
GFP mRNA from the HIV-1 promoter was measured using the primers 5’ 
GGAGCGCACCAT CTTCTTCA(forward) and 5’ AGGGTGTCGCCCTCGAA reverse 
along with the 5’ FAM labeled probe 5’ CTACAAGACCCGCGCCGAGGTG. A 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) primer pair and 5’ HEX-
labeled probe were included with each reaction for normalization: 5’ 
GCACCACCAACTGCTTAGCACC (forward), 5’ TCTTCTGGGTGGCAGTGATG 
(reverse), and 5’ TCGTGGGAAGGACTCATGACCACAGTCC (probe) (27). Relative 
mRNA expression was calculated using the 2-$$ct method. The data shown is the 
mean of at least three independent experiments, and the error bars represent the 
standard error of the mean. 
Cell proliferation assays 
Cellular proliferation and viability of the 2D10 cells were determined 96 hours 
post transduction using the CellTiter-blue cell viability assay (Promega; Madison, 
WI) according to the manufacture’s instructions. The assay was read using a 
Spectramax M3 microplate reader (Molecular devices, Sunnyvale, CA) at 
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fluorescence 560/590 nM. Viability was calculated as the percent of viability relative 
to the scrambled shRNA condition. At least three independent experiments were 
performed for each condition. The values shown in the graphs represent the mean ± 
the SEM. 
Statistical analysis  
GraphPad Prism software was used to analyze the data. The Student’s t test 
was used to compare the mean GFP protein or mRNA expression in 2D10 cells 
following transduction with a scrambled shRNA to cells transduced with HDAC1, -2, 
and -3 shRNAs. Furthermore, the Student’s t test was used to compare the mean 
GFP expression following incubation with HDAC inhibitors after transduction from at 
least three independent experiments. A p-value of less than .05 was considered 
statistically significant. 
Results 
HDAC3 negatively regulates HIV-1 expression in 2D10 cells.  
To determine the individual contribution of each HDAC to the maintenance of 
HIV-1 latency, first isozyme-specific HDAC knockdowns in the 2D10 cell line model 
of HIV-1 latency was evaluated. 2D10 cells contain a single, transcriptionally silent 
HIV-1 genome that is integrated into the cellular DNA (18). The 2D10 cell line was 
clonally selected for a low level of basal HIV-1 expression. However, viral expression 
is inducible by exposure to appropriate stimuli, such as tumor necrosis factor alpha 
(TNF-!) or HDAC inhibitors (18). 2D10 cells were transduced with a scrambled 
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shRNA control sequence or with shRNAs targeting HDAC1, -2, or -3. The HDAC 
mRNA levels following knockdown with the shRNAs were compared to the 
expression levels from the scrambled shRNA control condition 96 h post-
transduction. Following transduction, HDAC1, -2, and -3 mRNA levels were reduced 
by 70%, 92%, and 60%, respectively (Fig. 3.1A). The knockdowns were specific to 
the HDAC targeted (Fig 3.1A). Furthermore, cellular viability was not affected by 
transduction with shRNAs targeting HDAC1, -2, or -3 when compared to cells that 
had been transduced with the scrambled shRNA control 96 h post-transduction as 
measured by the cellTiter-blue cell viability assay (Promega, Madison, WI) (Fig. 
3.1B).  
 Because transcription from the HIV-1 promoter is induced by HDAC inhibitors 
that target the class I HDACs, HDAC1, -2 and -3, it was important to determine if 
depletion of a single HDAC was sufficient to induce transcription from the HIV-1 
LTR. Therefore, the impact of individual HDAC knockdown on HIV-1 expression in 
2D10 cells was assessed by monitoring GFP protein and mRNA expression from the 
HIV-1 LTR at 96 h post-transduction. Depletion of HDAC3 in 2D10 cells led to a 
statistically significant increase in the percentage of cells expression GFP protein 
and in mRNA expression from the HIV-1 promoter when compared to the scrambled 
shRNA control cells (Fig. 3.1C). However, individual HDAC1 or -2 knockdown did 
not induce a significant amount of HIV-1 LTR driven GFP protein or mRNA 
expression in 2D10 cells. Thus, depletion of HDAC3 alone, but not HDAC1 or -2, is 
sufficient to induce transcription from the HIV-1 LTR.  
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Concurrent knockdown of HDAC1 or HDAC2 with HDAC3 does not further 
increase expression from the HIV-1 promoter compared to depletion of HDAC3 
alone.  
Previously, it was reported that inhibitors selective for HDAC1, -2, and -3 are 
potent inducers of HIV-1 expression (4). Therefore, to determine if dual inhibition of 
a pair of these HDACs resulted in improved induction of HIV-1, compared to 
inhibition of HDAC3 alone, the effects of combined shRNA-mediated HDAC 
knockdown on latent HIV-1 expression were evaluated in 2D10 cells. The targeted 
HDAC mRNA expression levels following combination knockdowns were similar to 
those obtained following individual knockdowns at 96 h post transduction (compare 
Figs. 3.1A and 3.2A). Cell viability was not affected at 96 h following combination 
HDAC depletion when compared to the scrambled shRNA control as determined 
using the cellTiter-blue viability assay (Promega, Madison, WI) (Fig. 3.2B). Depletion 
of HDAC2 and -3 resulted in a significant increase in the percent of cells expressing 
HIV-1 LTR driven GFP protein and in HIV-1 driven GFP mRNA expression over the 
cells that were transduced with the scrambled shRNA (Fig. 3.2C). However, this 
increase was not significantly different from the increase observed following 
depletion of HDAC3 alone. The combined knockdown of HDAC1 and -3 resulted in a 
modest, but not significant, increase in the percent of cells expressing GFP protein 
and HIV-1 driven mRNA expression over cells that were transduced with the 
scrambled control (Figs. 3.2C). Similar to single knockdown of HDAC1 or -2, no 
induction of GFP protein or mRNA expression was observed when HDAC1 and -2 
were inhibited together. Therefore, depletion of HDAC1 or -2 in combination with 
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HDAC3 does not enhance the inducing effects observed following depletion of 
HDAC3 alone. 
Combined knockdown of HDAC1, -2, and -3 induces expression from the HIV-1 
LTR.  
As it has been previously observed that induction of HIV-1 expression in 
2D10 cells is induced with inhibitors that selectively target HDAC1, -2, and -3, it is 
possible that optimal induction of HIV-1 may require simultaneous inhibition of all 
three HDACs (4). Thus, the effects of combined knockdown of HDAC1, -2, and -3 on 
HIV-1 expression were tested. HDAC mRNA levels were reduced at 96 h post-
transduction with HDAC shRNAs when compared to transduction with the scrambled 
shRNA control (Fig. 3.3A). Concurrent knockdown of HDAC1, -2, and -3 did not 
affect cellular viability at 96 h post-transduction when compared to the scrambled 
shRNA control using the cellTiter-blue viability assay (Promega, Madison, WI)(Fig. 
3.3B). A significant increase in the percent of cells expressing GFP protein and in 
mRNA expression from the HIV-1 promoter was observed in cells depleted of 
HDAC1, -2, and -3 as compared to the scrambled shRNA control (Fig. 3.3C). 
However, as with the dual combination knockdowns, the amount of expression 
induced by all three HDACs was not significantly more than that observed following 
depletion of HDAC3 alone. Therefore, the significant increase observed following 
depletion of all three HDACs over the scrambled shRNA control condition is likely 
due to the effects of HDAC3 depletion. 
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 Enzymatic inhibition of HDACs potentiates the effects of HDAC3 
depletion.  
As the depletion of the HDACs was not complete when using shRNAs, next 
sub-optimal concentrations of HDAC inhibitors were used to enzymatically inhibit the 
remaining HDAC activity following targeted shRNA mediated depletion. Selective 
inhibition of HDAC1 and -2 with 20 #M of the drug Mrk12 in combination with 
depletion of HDAC1 did not significantly affect the percentage of cells expressing 
GFP from the HIV-1 promoter (Fig. 3.4A) (4). However, when Mrk12 was added to 
cells that were depleted of HDAC2 or -3 a significant increase in the percentage of 
cells expressing GFP from the HIV-1 promoter was observed over cells treated with 
the scrambled shRNA control and Mrk 12 (Fig. 3.4A). Furthermore, 200 nM of 
Mrk13, an inhibitor selective for HDAC1, -2, and -3, again induced a significant 
increase the percent of cells expressing GFP from the HIV-1 promoter in cells that 
were depleted of HDAC2 and -3 but not HDAC1 over expression from cells that had 
been transduced with the scrambled shRNA control and treated with Mrk 13 (Fig. 
3.4B).  
 Next, either a suboptimal concentration (250 nM) or a maximal concentration 
(500 nM) of the HDAC inhibitor suberoylanilide hydroxamic acid (SAHA or 
vorinostat), which is selective for HDAC1, -2, -3 -6, and -8, was used. Similar to the 
results found with Mrk12 and 13, the suboptimal concentration of SAHA induced a 
significant increase in the percentage of GFP expressing cells in cells that were 
depleted of HDAC2 and -3 but not HDAC1 over expression of GFP from the cells 
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that were transduced with a scrambled shRNA control and treated with SAHA (Fig. 
3.4C). When the maximal concentration of SAHA was combined with depletion of 
HDAC1, -2, or -3, a significant increase in the percent of cells expressing GFP from 
the HIV-1 promoter from the cells depleted of HDAC3, but not HDAC1 or -2, over 
2D10 cells treated with the scrambled shRNA control and SAHA was observed (Fig. 
3.4C). Furthermore, inhibition with the global HDAC inhibitor TSA also significantly 
enhanced the effect of HDAC3 depletion (Fig. 3.4D). As depletion of HDAC2 
significantly increased the percentage of cells expressing GFP from the HIV-1 
promoter in conjunction with three of the conditions, a supportive role for HDAC2 in 
repression of HIV-1 transcription cannot be ruled out.  
 To determine whether further inhibition of HDAC3 without inhibition of HDAC1 
or -2 was sufficient to induce transcription from the HIV-1 LTR, an HDAC inhibitor 
that is selective for HDAC3, but not HDAC1 or -2 was used. Droxinostat inhibits 
HDAC3, -6 and -8 but inhibits HDAC3 at the lowest concentration, with an IC50 of 2 
#M (15). Therefore, 2 #M of Droxinostat was used to inhibit HDAC3 activity after 
depletion of HDAC1, -2 or -3. Again, depletion of HDAC1 or -2 with inhibition of 
HDAC3 did not increase the percent of cells with LTR driven GFP protein expression 
observed over Droxinostat treatment of the cells transduced with the scrambled 
shRNA (Fig. 3.4E). However, inhibiting the enzymatic activity of the remaining 
HDAC3 enzyme with Droxinostat following HDAC3 depletion induced a significant 
increase in the percent of cells expressing GFP protein from the HIV-1 LTR 
compared to cells that were transduced with the scrambled control and treated with 
Droxinostat (Fig. 3.4E). Altogether, these results support the above results, 
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indicating that inhibition of HDAC3 is key for reactivation of latent HIV-1 and that 
inhibition of HDAC1 or -2 does not enhance the effect of reducing the activity of 
HDAC3 through depletion or enzymatic inhibition.  
Discussion 
HDAC inhibitors selective for the class I HDACs HDAC1, -2, and -3, but not 
those that are selective for HDAC1 and -2, are potent inducers of HIV-1 transcription 
(4, 25). In an effort to determine the minimal HDAC-inhibitory requirement for optimal 
induction of latent HIV-1, an shRNA-mediated strategy was employed to deplete 
individual and combinations of the class I HDACs, HDAC1, -2, and -3, in the 2D10 T 
cell line model of quiescent HIV-1. Isolated depletion of HDAC3 expression resulted 
in a statistically significant induction of LTR driven GFP protein expression in 2D10 
cells (Fig. 3.1D). These findings support our previous studies on the effects of 
selective HDAC inhibitors and further define the minimal HDAC inhibition that is 
required for reactivation of latent HIV-1 (4).  
To determine whether depletion of HDAC1 or -2 could possibly enhance the 
effects of depletion of HDAC3, shRNAs were used to deplete these HDACs in 
combination. Similar to the results of Huber et al., concurrent depletion of HDAC1 
and -2 did not induce expression from the HIV-1 promoter (15). After depletion of 
HDAC2 and -3 a significant increase in the percent of cells with HIV-1 driven GFP 
protein expression and GFP mRNA expression were observed (Fig. 3.2C). However, 
the amount of induction seen after dual inhibition is not significantly more than the 
amount of induction following depletion of HDAC3 alone, which indicates that the 
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observed induction may be due to HDAC3 depletion. Furthermore, depletion of 
HDAC1 and -3 did not induce a significant increase in LTR-driven GFP expression 
compared with transduction with the scrambled shRNA control. Therefore, depletion 
of HDAC1 may interfere with the effect of depletion of HDAC3 alone. Another study 
reported similar results when analyzing expression of cyclin D1 by quantitative RT-
PCR following knockdown of HDAC1, HDAC2, or HDAC1 and -2 in combination. In 
that study, isolated knockdown of HDAC1 reduced cyclin D1 mRNA levels by 75% 
and knockdown of HDAC2 led to a 50% reduction in cyclin D1. However, when 
HDAC1 and -2 were knocked down concurrently, no reduction in cyclin D1 
expression was observed (7). Thus, concurrent depletion of two HDACs can 
suppress the repressive effects of either HDAC, perhaps due to the counter-
regulatory effects of the acetylation of HDACs themselves (7). 
We and others have previously reported that latent HIV-1 expression is 
induced with HDAC inhibitors that selectively target the class I HDACs (i.e. HDAC1, 
-2, and -3) (4, 25). Therefore, to determine whether induction of the HIV-1 promoter 
was improved by inhibition of all three HDACs, shRNAs were used to deplete all 
three HDACs at once. The depletion observed following transduction with shRNAs 
targeting HDAC1, -2, and -3 was similar to that observed following individual 
depletion and cell viability was not affected. Similar to the results found using 
enzymatic inhibition, simultaneous depletion of HDAC1, -2, and -3 by shRNA in 
2D10 cells induced a significant amount of HIV-1 driven GFP protein and mRNA 
expression (Fig. 3.3C). However, the percent of cells expressing GFP was not as 
high as it was after depletion of HDAC3 alone, suggesting that depletion of multiple 
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HDACs may be less effective than depletion of HDAC3 alone or may be a artifact of 
the shRNA mediated knockdown strategy.  
It’s worth noting that the rate of knockdown achieved by the individual HDAC 
shRNAs in this study ranged from 48% to 95% (Figs. 3.1A, 3.2A, and 3.3A); thus, 
there was not a complete elimination of any of the HDACs targeted. Because 
HDAC1, -2, and -3 are all known to associate with the HIV-1 LTR (4), it is possible 
that some combination of these HDACs may remain to regulate the viral promoter 
following knockdown with shRNA. Furthermore, transduction with shRNAs results in 
a slow depletion of protein expression. In contrast, chemical HDAC enzymatic 
inhibition occurs rapidly and persists until the drug is cleared and the active enzyme 
is reconstituted.  
To address some of these concerns, 2D10 cells were depleted of HDAC1, -2, 
or -3 and then small molecules were used to inhibit the remaining HDAC activity. 
Depletion of HDAC2, or -3 followed by enzymatic inhibition of HDAC1 and -2 with 
the small molecule Mrk12 resulted in a significant increase in the percentage of cells 
with GFP protein expression from the HIV-1 LTR over cells that were treated with 
the scrambled shRNA and Mrk12 (Fig. 3.4A). However, no change was observed in 
the cells depleted of HDAC1 followed by treatment with Mrk12 over treatment of 
cells treated with the scrambled shRNA and Mrk 12 (Fig. 3.4A). Similar results were 
obtained using an inhibitor specific for HDAC1, -2, and -3 (Mrk 13) and a suboptimal 
concentration of the broad HDAC inhibitor SAHA (250 nm) (Fig. 3.4B-C). These 
results demonstrate that inhibiting the remaining HDAC activity after depletion of 
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HDAC2 or -3 enhances the effects of depletion alone. Furthermore, use of a 
maximal concentration of SAHA (500 nM) or the broad HDACi TSA augmented the 
effect of depletion of HDAC3 alone (Fig. 3.4C-D). Because the maximal 
concentration of SAHA or the broad acting HDACi TSA are high, the contributory 
effect of HDAC2 that was observed in the previous conditions may have been 
masked. However, the effects of HDAC3 depletion were sufficient to enhance the 
activity of all of the small molecules that were tested in this study. 
To date, no specific inhibitors of HDAC3 have been described. However, 
Huber et al. recently demonstrated that Droxinostat, which is a selective inhibitor of 
HDAC3, -6, and -8 at low concentrations, activated transcription from a cell model of 
HIV-1 latency (15). The concentrations of Droxinostat used in that study, 60 µM, 
were sufficient to inhibit HDAC1 as well. Therefore, following that study, it was still 
unknown whether inhibition of HDAC1 in addition to HDAC3 was required for 
activation of transcription from the HIV-1 LTR. In this study, treating cells depleted of 
HDAC3 with 2 #M of Droxinostat resulted in a significant increase in GFP expression 
from the HIV-1 LTR over cells transduced with the scrambled shRNA (Fig. 3.4E). In 
this study, a significant increase in GFP protein expression from the HIV-1 LTR was 
detected with 2 #M of Droxinostat, which is the IC50 of this drug for HDAC3 and is 
2.5 fold below the IC50 value for HDAC8 and 30 fold below the IC50 for HDAC1 (15). 
However, as with previous studies, it is difficult to rule out a contributory effect of 
HDAC6 or -8 when treating with Droxinostat. Altogether, these results support the 
conclusion that HDAC3 is the primary target of class I HDAC inhibitors that 
reactivate transcription of latent HIV. 
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 Microarray studies have demonstrated that increased acetylation at the 
promoter of genes is associated with active transcription. Furthermore, acetylated 
histone tails recruit bromodomain containing proteins such as BRG1 of the SWI/SNF 
complex and TFIID, which promote transcription from the promoter (1). HDAC1, -2, 
and -3 have been demonstrated to physically associate with the HIV-1 LTR (17), and 
inhibition of these HDACs with small molecule HDAC inhibitors is associated with 
increased acetylation of histones at the HIV-1 LTR (19). Therefore, it is interesting 
that depletion of HDAC3, but not HDAC1 or -2, activates transcription from the HIV-1 
promoter. However, HDAC3 has been demonstrated to have some key differences 
from HDAC1 and -2 that may account for its unique role.  
HDAC1 and -2 are 85% similar to each other; however, HDAC3 is only 53% 
and 52% similar to HDAC1 and -2, respectively. Furthermore, HDAC3 contains a 
unique amino acid sequence at its carboxy terminus (29). In addition to its nuclear 
localization signal, HDAC3 contains cytoplasmic and cell membrane-targeting 
regions that are not found in HDAC1 and -2 (29). HDAC2 and -3 are located in both 
the cytoplasm and nucleus in resting and activated CD4+ T cells from HIV-1 infected 
aviremic patients (17). In contrast, HDAC1 is only found in the nucleus (17). In 
addition to affecting localization, these sequence differences may also account for 
HDAC3’s unique complex association. HDAC3 is associated with the NCoR and 
SMRT complexes, while HDAC1 and -2 are associated with the CoREST, NuRD, 
REST, and Sin complexes (11, 14). NCoR has been demonstrated to bind to the 
HIV-1 LTR in monocyte-derived macrophages (12). Furthermore, NCoR is found at 
the HIV-1 LTR in a Jurkat cell line model of HIV-1 latency (J89 cells)(Barton and 
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Margolis, unpublished data). The association of NCoR with the HIV-1 promoter 
indicates that HDAC3 may be mediating its effects through the NCoR complex. Of 
the HDACs that are found at the HIV-1 promoter, HDAC1 and -3 have the most 
highly expressed mRNAs and are expressed five and eight times more than that of 
HDAC2, respectively (17). Therefore, the minimal role of HDAC2 in reactivation of 
latent HIV-1 could be associated with the minimal amount of expression relative to 
the other two HDACs. Additionally, studies looking at histone deacetylation patterns 
have found that HDAC3 preferentially deacetylates histone 4 lysine 5 > lysine 8 > 
lysine 12 > lysine 16 (13). The substrate specificity of HDAC1 and -2 are not fully 
elucidated. Considering the many differences between HDAC1, -2, and -3, it is not 
surprising that the effect of HDAC3 depletion on the HIV-1 LTR is distinct from that 
of HDAC1 and -2. Therefore, the differences in effects observed following individual 
depletion of these HDACs may be due to the differences in complex association, 
sequence diversity, expression, or substrate preference. 
In addition to the differences in complex associations and sequence diversity, 
HDAC3 has been demonstrated to have non-histone targets that may explain its role 
in activation of transcription from the HIV-1 LTR. HDAC3 specifically deacetylates 
the RelA component of the NF-!b transcription factor, which then results in 
disassociation of RelA from promoters, association with IkB" and export from the 
nucleus (5). Localization of the RelA/p50 heterodimer of NF-!b to the HIV-1 
promoter and displacement of the NF-!b p50/p50 homodimer activates transcription 
from the HIV-1 promoter (21). Furthermore, several compounds such as TNF" and 
PMA have been demonstrated to activate transcription from the HIV-1 promoter 
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through promoting relocation of the NF-!b RelA/p50 heterodimer to the nucleus (8, 
22). Therefore, in addition to its role as a histone deacetylase, HDAC3 depletion 
may further affect HIV-1 transcription by preventing deacetylation of RelA and 
dissociation of the activating NF-!b heterodimer from the HIV-1 LTR. 
The next step of this project was to determine the minimal HDAC inhibition 
required to induce latent HIV-1 expression. Selective HDAC inhibitors targeting 
HDAC1 and -2 were not sufficient to induce latent HIV-1 expression (4). Because 
small molecules that target HDAC3 alone have only recently been developed, 
previous studies have not been able to determine the minimal HDAC inhibition that 
is required for induction of transcription from latent HIV-1 proviruses. In this study, 
selective targeting of HDAC3 was demonstrated to be sufficient to induce expression 
from the HIV-1 promoter.  
A future important research goal is to validate the centrality of HDAC3 in the 
induction of HIV-1 transcription from patient cells. As part of this study, depletion of 
HDAC1, -2, and 3 from patient cells was attempted. Transduction of peripheral blood 
mononuclear cells with shRNAs did not result in depletion of the targeted HDACs. 
However, nucleofection of siRNAs into resting primary T cells using the Amaxa 
Nuclefector (Lonza, Switzerland) did result in a significant and specific depletion of 
the targeted HDAC (Keedy and Margolis, unpublished data). Furthermore, 
nucleofection did not significantly affect cell viability as compared to cells transduced 
with a control siRNA. A modest induction of HIV-1 outgrowth in a co-culture assay 
was observed in resting memory T cells following individual depletion of each 
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HDAC2 or -3 (Keedy and Margolis, unpublished data). However, perturbation of the 
resting state in these memory T cells was also observed following the nucleofection 
procedure, as indicated by an increase in CD69 expression 24 h post nucleofection. 
Therefore, the results are difficult to interpret because it is unclear whether viral 
expression is due to the unique or combined effects of the nucleofection procedure 
or of HDAC depletion. Therefore, the identification or development of more selective 
class I HDAC inhibitors is required to determine the extent of expression that is 
induced by complete and selective enzymatic inhibition of HDAC3. 
 Selective HDAC inhibitors that target a limited number of the class I HDACs 
have potential as anti-latency therapies with fewer host-toxicities and non-HIV 
specific effects than pan-HDAC inhibitors. It was previously demonstrated that 
inhibitors that selectively target HDAC1, -2, and -3—but not HDAC1 and -2 alone—
are potent inducers of latent HIV-1 (4). In this study, whether a more selective 
induction of HIV-1 could be achieved using a shRNA-mediated strategy of HDAC 
knockdown was evaluated. The results indicate that depletion of HDAC3 significantly 
induces expression from the HIV-1 promoter. Thus, potently and selectively targeting 
HDAC3 alone may be sufficient to induce transcription from quiescent proviruses. 
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Figure 3.1. Depletion of HDAC3 significantly increases expression from the 
HIV-1 promoter. A. Expression of the indicated HDAC mRNAs following shRNA 
mediated depletion of HDAC1, -2, or -3 in 2D10 cells. Depletion of HDAC1, -2, or -3 
was significant and specific for the targeted HDAC. B. Cell proliferation was not 
significantly affected following depletion of HDAC1, -2 or -3 in 2D10 cells. C. The 
percentage of 2D10 cells expressing GFP protein from the HIV-1 promoter following 
depletion significantly increased following depletion of HDAC3 in comparison to 
control cells transduced with the scrambled shRNA, but not following depletion of 
HDAC1 or -2. This same effect was seen when GFP mRNA expression was directly 
measured. Expression was not significantly altered from baseline following 
transduction with non-specific shRNA. 
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Figure 3.2. Co-depletion of HDAC2 and HDAC3 significantly increases 
expression from the HIV-1 promoter. A. Expression of the indicated HDAC 
mRNAs following shRNA mediated depletion of HDAC1 and -2, HDAC1 and -3, or 
HDAC2 and -3. The depletion was significant and specific for the targeted HDACs. 
B. Cell proliferation and viability of 2D10 cells that were transduced with shRNAs 
targeting HDAC1 and -2, HDAC1 and -3, or HDAC2 and -3. No significant changes 
in cell proliferation and viability were observed following co-depletion of these 
HDACs as compared to cells that were transduced with the scrambled shRNA 
control. C. Expression of GFP from the HIV-1 promoter following depletion of 
HDAC2 and -3 increased compared to the control cells transduced with a scrambled 
shRNA. However, depletion of HDAC1 and -2 or HDAC1 and -3 did not have a 
significant effect on GFP expression. This same result was seen when GFP mRNA 
expression was directly measured. Expression was not significantly altered from 
baseline following transduction with non-specific shRNA. 
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Figure 3.3. Depletion of HDAC1, -2, and -3 significantly increases expression 
from the HIV-1 promoter. A. Fold change of HDAC1, -2, and -3 mRNA expression 
as compared to 2D10 cells transduced with the scrambled shRNA control. A 
significant reduction in the mRNA expression of all three HDACs was observed. B. 
Cell viability and proliferation as a percentage of the 2D10 cells transduced with the 
scrambled shRNA control. Depletion of HDAC1, -2, and -3 did not significantly affect 
cell viability and proliferation. C. A significant increase in the percentage of cells 
expressing GFP protein from the HIV-1 promoter was observed following depletion 
of HDAC1, -2, and -3. Furthermore, a significant increase in expression of GFP 
mRNA from the HIV-1 promoter was observed following depletion of HDAC1, -2, and 
-3. 
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 Figure 3.4. Chemical inhibition of HDACs following depletion of HDAC3 
significantly increases expression from the HIV-1 promoter. A. Chemical 
inhibition of HDAC1 and -2 using Mrk 12 (20 #M) does not result in a significant 
increase in the percentage of 2D10 cells expressing GFP following depletion of 
HDAC1 or -2. However, similar to depletion of HDAC3 alone, a significant increase 
in the percent of cells expressing GFP was when Mrk 12 was added to cells 
depleted of HDAC3. B. Chemical inhibition of HDAC1, -2, and -3 with Mrk13 (200 
nM) resulted in a significant increase in the percent of GFP positive 2D10 cells in 
cells depleted of HDAC2 or -3, but not HDAC1. C. A minimal (250 nM) dose of 
SAHA resulted in a significant increase in the percent of GFP positive cells in cells 
that were depleted of HDAC2 and a maximal dose (500 nM) resulted in a significant 
increase in the percent cells expressing GFP in cells depleted of HDAC2 or -3. 
However, neither dose resulted in a significant increase in GFP expression in 2D10 
cells that were depleted of HDAC1. D. Chemical inhibition of HDACs with the non-
selective HDAC inhibitor TSA (25 nM) resulted in a significant increase in the 
percent of GFP expressing 2D10 cells in cells depleted of HDAC3, but not HDAC1 
or HDAC2. E. Chemical inhibition of HDAC3, HDAC6 and HDAC8 with the selective 
HDAC inhibitor Droxinostat resulted in a significant increase in the percent of cells 
expressing GFP in 2D10 cells that had been depleted of HDAC3 but not HDAC1 or 
HDAC2. 
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CHAPTER 4 
DISCUSSION 
Introduction 
 The HIV-1 epidemic has caused significant social and economic difficulties for 
communities and nations around the world. Over the last thirty years, substantial 
advances have been made in understanding the virus, which has led to the 
development of very effective ART regimens. However, a “cure” has not been 
developed thus far. The primary impediment to complete clearance of the virus is the 
existence of a long-lived population of cells harboring replication competent but 
transcriptionally silent virus. One of the most promising strategies to address the 
problem of latent virus is induction of viral transcription and replication followed by 
clearance of the virus. This thesis primarily focused on identifying cellular 
therapeutic targets to induce transcription from quiescent HIV-1 promoters. 
Findings and Implications 
Initially this project aimed to determine whether targeting cMyc, YY1 or both 
could induce expression from the HIV-1 promoter in a Jurkat cell line model of 
quiescent HIV-1 and to determine whether the factors cMyc and YY1 are important 
for recruitment of HDAC2 and HDAC3 to the HIV-1 promoter. To determine whether 
cMyc and YY1 are important for maintenance of the quiescent proviral state, 
transduction of shRNAs was used to deplete cMyc and YY1 individually or in 
combination and then transcription was measured from the HIV-1 promoter using 
qPCR and flow cytometry. Depletion of cMyc or YY1 following transduction with the 
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shRNAs was measure by qPCR to determine the levels of mRNA and by Western 
blot to measure the amount of protein. A significant and specific reduction in the 
targeted product was observed following transduction of the 2D10 or J89 cells with 
shRNAs. Because cells release stress related factors when viability is reduced that 
can activate HIV-1 transcription, it was important to determine whether depletion of 
cMyc, YY1 or both had and effect on the viability of 2D10 and J89 cells. When cMyc, 
YY1 or both were depleted from J89 or 2D10 cells no significant change in viability 
was observed, indicating that changes in expression from the HIV-1 promoter where 
due to depletion of the cMyc or YY1 and not to cellular stress.  
Previous studies in HeLa cell line models of HIV-1 latency demonstrated that 
cMyc and YY1 are important factors for the maintenance of proviral quiescence in 
those models (5-9). To further extend these findings to Jurkat cells, expression from 
the HIV-1 promoter was measured following depletion of cMyc, YY1 or both. When 
YY1 was depleted from 2D10 or J89 cells, a significant increase in mRNA and 
protein expression was observed by qPCR and Western blot, respectively. However, 
depletion of cMyc or YY1 and cMyc did not significantly affect expression in either 
cell line. This finding illustrates the necessity of demonstrating that identified 
mechanisms are relevant in multiple systems. 
 Both cMyc and YY1 have been shown to interact with HDAC-containing 
complexes and to be important for occupancy of HDAC1 at the HIV-1 LTR. 
Therefore, because the class I HDACs are very similar in sequence and because 
HDAC2 is found in complex with HDAC1, the hypothesis that cMyc and YY1 may be 
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important for occupancy of HDAC2 and HDAC3 at the HIV-1 promoter was 
developed. To determine whether depletion of cMyc or YY1 affected occupancy of 
HDAC2 and HDAC3 at the HIV-1 LTR in Jurkat cells, ChIP was used to measure 
occupancy of the class I HDACs in cells that had been depleted of cMyc or YY1. It 
was found that depletion of cMyc or YY1 did not significantly affect occupancy of 
HDAC2 or HDAC3 at the HIV-1 LTR in 2D10 or J89 cells. Because many 
transcription factors that bind to the HIV-1 promoter recruit HDACs, it was 
hypothesized that redundant recruitment mechanisms may compensate for the loss 
of a single factor. Therefore, the occupancy of HDAC2 and HDAC3 at the HIV-1 LTR 
was measured in J89 and 2D10 cells that had been depleted of both cMyc and YY1. 
The levels of HDAC2 and HDAC3 did not significantly change following depletion of 
both factors. These results indicate that in addition to cMyc and YY1, other factors 
contribute to recruitment of HDAC2- and HDAC3-containing complexes. 
Furthermore, additional or separate factors may need to be targeted to induce 
transcription from the HIV-1 promoter. Alternatively, because shRNAs only reduce 
and do not completely eliminate protein, more advanced technologies that can 
completely eliminate cMyc or YY1 may have potential for therapeutic treatment of 
HIV. Therefore, although cMyc and YY1 are involved in recruitment of HDACs to the 
HIV-1 LTR, depletion of cMyc or YY1 is not sufficient to significantly alter HDAC 
occupancy of the HIV-1 LTR.  Therefore, the redundant mechanisms that exist at the 
HIV-1 promoter may be sufficient to maintain HDAC occupancy and repression of 
HIV-1 transcription in the absence of cMyc or YY1.  
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Future directions 
The goal of this study was to find a selective way to target the HIV-1 LTR 
while minimizing the effect on cellular genes. The results from this study indicate that 
cMyc and YY1 may not be ideal candidates for inducing transcription from quiescent 
proviruses. To this end, targeting the other transcription factors such as NF-!b or 
CBF-1 either alone or in conjunction with cMyc or YY1 may be required to disrupt 
HDAC occupancy at the HIV-1 promoter and induce transcription (10, 11). However, 
many of the transcription factors found at the HIV-1 promoter are ubiquitous and 
affect many cellular promoters (11). Therefore, it will be important to assess the 
effect of these potential approaches on cellular genes and whether it is less 
disruptive than globally targeting HDACs.  
Findings and implications 
The next objective was to determine which individual or a combination of 
HDACs is important for maintenance of quiescent HIV. To address this question, a 
shRNA mediated strategy was used to deplete HDAC1, HDAC2 or HDAC3 
individually or in combination. Depletion of the individual HDACs did not affect the 
viability of 2D10 cells or the expression of the non-targeted HDACs. Furthermore, 
the shRNA-mediated depletion of HDAC1, HDAC2 or HDAC3 resulted in a 
significant decrease in mRNA expression of the targeted HDAC. Depletion of 
HDAC1 or HDAC2 did not significantly increase mRNA or GFP expression from the 
HIV-1 promoter. However, depletion of HDAC3 did significantly induce protein and 
mRNA expression from the HIV-1 promoter, which indicates that HDAC3 activity 
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may be the key target of HDAC inhibitors that reactivate expression from the HIV-1 
promoter. To further determine whether co-depletion of the HDACs would enhance 
the effects observed following single depletion, shRNAs were used to deplete 
combinations of the class I HDACs. Depletion of HDAC1 and HDAC3 or HDAC1 and 
HDAC2 did not affect expression from the HIV-1 LTR. However, depletion of HDAC2 
and HDAC3 did result in a significant increase in protein and mRNA expression from 
the HIV-1 promoter. The amount of expression from the HIV-1 LTR following co-
depletion of HDAC2 and HDAC3 was not significantly greater than that observed 
following depletion of HDAC3 alone, indicating that the effects observed may be due 
to depletion of HDAC3. It is interesting that the same did not hold true when HDAC1 
and HDAC3 were depleted, which indicates that depletion of HDAC1 may interfere 
with reactivation that is observed following depletion of HDAC3. These results 
indicate that more selective HDAC inhibitors may be sufficient to induce transcription 
from quiescent proviruses. 
Because the shRNA strategy does not completely eliminate the targeted 
enzyme(s) from the cells, low levels of small molecules were used to inhibit the 
residual HDAC activity following depletion of HDAC1, HDAC2 or HDAC3. Merck 12 
is an HDAC inhibitor that is selective for HDAC1 and HDAC2 (3). When depletion of 
HDAC1 was combined with inhibition of HDAC1 and HDAC2 using Merck 12, no 
significant increase in expression from the HIV-1 promoter over treatment with 
Merck 12 only was observed (3). However, depletion of HDAC2 or HDAC3 coupled 
with inhibition using Merck 12 resulted in a significant increase in expression from 
the HIV-1 promoter when compared to treatment of with Merck 12 only. Next, Merck 
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13 was evaluated, which is an inhibitor of HDAC1, HDAC2 and HDAC3, in 
conjunction with depletion of the individual HDACs (3). Treatment with Merck 13 
enhanced the induction of expression from the HIV-1 LTR in cells that had been 
depleted of HDAC2 or HDAC3, but not those depleted of HDAC1, over cells treated 
with Merck 13 and the scrambled shRNA.  
Suberoylanilide hydroxamic acid (SAHA) has recently been demonstrated to 
activate viral transcription in vivo in a clinical trail (1). SAHA is an HDAC inhibitor that 
is selective for HDAC1, HDAC2, HDAC3 and the class II HDAC, HDAC6 (2). A low 
level of SAHA (250 nM) and a high level of SAHA (250 nM) were both used in 
combination with depletion of HDAC1, HDAC2, or HDAC3. Following depletion of 
HDAC2 or HDAC3, cultures that were exposed to 250 nM of SAHA had a significant 
increase in the percent of cells expressing GFP under the control of the HIV-1 LTR, 
but not in cells depleted of HDAC1. Furthermore, when the cells depleted of HDAC3 
were exposed to the high dose of SAHA (500 nM), a significant increase in the 
number of cells expressing GFP was observed. However, this increase was not 
observed in cells that were depleted of HDAC1 or HDAC2. To further understand the 
effect of interfering with HDAC activity, a low concentration of the global HDAC 
inhibitor trichostatin A (TSA, 50 nM) was also evaluated in cells depleted of HDAC1, 
HDAC2 or HDAC3 and a significant increase in protein expression from the HIV-1 
LTR in cells depleted of HDAC3, but not HDAC1 or HDAC2 was observed (13). 
These results further confirm the findings from the depletion experiments. 
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HDAC inhibitors that are selective for HDAC3 are relatively new and have not 
been fully characterized. However, Droxinostat, which is selective for HDAC3, but 
not HDAC1 or HDAC2, is commercially available. Droxinostat has also been shown 
to inhibit HDAC6 and HDAC8. Similar to the previous drug experiments, Droxinostat 
was used to inhibit residual HDAC3 activity in cells depleted of HDAC1, HDAC2 or 
HDAC3 (12). A significant increase in the percent of cells expressing GFP in cells 
that were depleted of HDAC3, but not HDAC1 or HDAC2. These results provide 
supporting evidence that depletion and enzymatic inhibition of HDAC3 result in 
expression from the HIV-1 LTR in 2D10 cells.  
Several of these inhibitors also induced a significant increase in the percent of 
cells expressing GFP in cells depleted of HDAC2, which indicates that HDAC2 may 
also play a role in suppression of the HIV-1 LTR, however, it can not be definitively 
concluded that HDAC2 activity is relevant because expression was only observed in 
a subset of the HDAC2 experiments.  
Overall, this study indicates that targeting HDAC3 alone is sufficient to relieve 
HDAC mediated repression of the HIV-1 promoter and that novel small molecules 
that are selective for HDAC3 may be a promising therapies for treatment of latent 
HIV-1 infection. 
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Future directions 
 The next step of this study, is to extend these findings to patient cells. 
Collaborations with Dr. Alan Kozikowski at the University of Illinois and the Dr. Ed 
Holson at the Broad Institute have been initiated to further characterize and test 
small molecules that are selective for inhibition of HDAC3 (4). Experiments to test 
three molecules from the Kozikowsky lab including 11, 14c and 14d are currently 
being conducted in cell line models of latent HIV-1 (4). Preliminary studies indicate 
that the compounds are able to activate transcription from the HIV-1 promoter at 
concentrations upwards of 5 uM (4). However, at these concentrations the cell 
viability is significantly affected. The compound from the Broad institute, which is 
currently unpublished, induces GFP expression in a significant number of 2D10 cells 
and has very little toxicity. Additional experiments in patient cells are currently 
underway. 
 The 2D10 cell line is a clonal cell line that contains a single integration site, 
which is not representative of the in vivo condition where the latent population 
consists of cells with HIV-1 proviruses integrated into variable locations. To make 
our findings more relevant to the in vivo state, it will also be prudent to extend these 
findings in additional cells lines and to primary cells from aviremic patients.  
 Initial studies using SAHA, which is selective for HDAC1, HDAC2, HDAC3 
and HDAC6, have not observed significant adverse events associated with 
treatment. However, determining which targets of SAHA are important for its in vivo 
activity are needed to facilitate the development of future therapeutics. 
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Concluding Remarks 
 The persistence of a replication competent viral reservoir in HIV-infected 
patients is the primary obstacle to a resolution of the HIV epidemic. Substantial 
efforts have led to significant advances in our understanding of how HIV-1 is able to 
persist in the presence of ART, and parallel efforts have identified many pathways 
that can be targeted to reactivate the virus. The findings in this dissertation have 
further characterized the role of cMyc and YY1 in the maintenance of HIV-1 
transcriptional repression. Furthermore, these studies indicate that HDAC3 may be 
the critical enzymatic target of HDAC inhibitors that are capable of activating 
transcription from the HIV-1 promoter. If these findings hold true in patient cells, it 
will be exciting to determine whether more specific HDAC inhibitors are as effective 
at activating latent HIV-1 in vivo.  
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